Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 1 Abbreviated Title:  Anti- MAGE -A3-DP4 TCR PBL  
CC Protocol Number: 14 -C-0052 K  
IBC Number : RD -13-X-03 
OSP Number : 1310-1253 
NCT Number: NCT 02111850 
Version Date:  June 22, 2018  
PROTOCOL TITLE  
A Phase I/II Study of the Treatment of Metastatic Cancer that Expresses MAGE -A3 Using 
Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti -
MAGE -A3 TCR -Gene Engineered Lymphocytes and Aldesleukin 
 
NIH Principal Investigator:   Steven A. Rosenberg, M.D., Ph.D.  
     Chief of Surgery, Surgery Branch, NCI 
 Building 10, CRC, Room 3-3940  9000 Rockville Pike, Bethesda, MD 20892  
     Phone: 240-760-6218; Email: Steven.Rosenberg@nih.gov   
  
Investigational Agent: 
 
Drug Name: Anti-MAGE -A3-DP4 TCR PBL  
IND Number:  15770 
Sponsor : Center for Cancer Research  
Manufacturer:  Surgery Branch Cell Production  Facility  
 
 Commercial Agents:  Cyclophosphamide, Fludarabine, and Aldesleukin 
 
  
A b brevi ate d Title: A nti -M A G E -A 3 -D P 4 T C R P B L  
Versi o n D ate: J u ne 2 2, 2 0 1 8  
 2 P R É CI S  
B ac k gr o u n d: 
• We ha ve c o nstr ucte d a si n gle retr o viral vect or t hat c o ntai ns b ot h α a n d  β c hai ns of a T 
cell rece pt or ( T C R) t hat rec o g nizes t he D P 0 4 0 1 / 0 4 0 2 restricte d M A G E -A 3 t u m or 
a nti ge n, w hi c h ca n be use d t o me diate ge netic tra nsf er of t his T C R wit h hi g h efficie nc y.  
• I n c o -c ult ures wit h H L A - D P 0 4 0 1/ 0 4 0 2 a n d M A G E - A 3 d o u ble p ositi ve t u m ors, t he a nti- 
M A G E -A 3 - D P 0 4 0 1/ 0 4 0 2 restricte d (a nti -M A G E -A 3 - D P 4) T C R tra ns d uce d T cells 
secrete d si g nifica nt a m o u nts of I F N -γ( wit h hi g h s pecificit y.  
O bjecti ves : 
• Pri mar y o bjecti ves : 
o D eter mi ne a s afe d os e of t he a d mi nistrati o n of a ut ol o g o us C D 4 cells tra ns d uce d wit h 
a n a nti- M A G E -A 3 - D P 0 4 0 1/ 0 4 0 2 restricte d ( M A G E -A 3 -D P 4) T C R  a n d al desle u ki n 
t o patie nts f oll o wi n g a n o n m yel oa blati ve b ut l y m p h oi d de pleti n g pre parati ve re gi me n. 
o D eter mi ne if t his a p pr oac h will res ult i n o bjecti ve  t u m or re gressi o n i n patie nts wit h 
metastatic ca ncer e x pressi n g M A G E- A 3 -D P 4 . 
o D eter mi ne t he t o xicit y pr ofile of t his treat me nt re gi me n.  
Eli gi bili t y : 
Patie nts w h o are H L A - D P 0 4 0 1/ 0 4 0 2 p ositi ve a n d 1 8 years of a ge or ol der m ust ha ve: 
• Metastatic ca ncer w h os e t u m ors e x press t he M A G E -A 3 -D P 4 a nti ge n;  
• Pre vi o usl y recei ve d a n d ha ve bee n a n o n -res p o n der t o or rec urre d f oll o wi n g at least o ne 
first li ne treat me nt f or metastatic dis ease;  
Patie nts ma y n ot ha ve:  
• C o ntrai n dicati o ns f or hi g h d os e al desle u ki n a d mi nistrati o n. 
Desi g n : 
• P B M C o btai ne d b y le u ka p heresis will be e nric he d f or C D 4 cells a n d tra ns d uce d wit h t he 
retr o viral vect or s u per nata nt e nc o di n g t he a nti -M A G E -A 3 -D P 4 T C R.  
• T he st u d y will be gi n i n a sta n dar d p has e 1 d os e escalati o n . After t he M T D cell d os e has 
bee n deter mi ne d, patie nts will be e nr olle d i nt o t he p has e 2 p orti o n of t he trial at t he M T D 
esta blis he d d uri n g t he p has e 1 p orti o n of t he st u d y.  I n t he p hase 2 p orti o n, p atie nts will be 
e ntere d i nt o t w o c o h orts: c o h ort 1 will i ncl u de patie nts wit h metastatic mela n o ma; c o h ort 
2 will i ncl u de patie nts wit h re nal ca ncer a n d ot her t y pes o f metastatic ca ncer.   
• Patie nts will recei ve a n o n m yel oa blati ve b ut l y m p h oc yte de pleti n g pre parati ve re gi me n 
c o nsisti n g of c ycl o p h os p ha mi de a n d fl u dara bi ne f oll o we d b y i ntra ve n o us i nf usi o n of e x 
vi v o t u m or reacti ve, T C R ge ne -tra ns d uce d P B M C pl us I V al desle u ki n.   
• Patie nts will u n der g o c o m plete e val uati o n of t u m or res p o nse e ver y 1 - 6 m o nt hs u ntil off 
st u d y criteria are met.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 3 • For each of the 2 strata evaluated  in the phase 2 portion , the study will be conducted 
using a phase 2 optimal design where initially 21  evaluable patients will be enrolled. For 
each of these two arms of the trial, if 0 or 1 of the 21 patients experiences a clinical 
response, then no further patients will be enrolled but if 2 or more of the first 21 evaluable patients enrolled have a clini cal response, then accrual will continue until a 
total of 41 evaluable patients have been enrolled in that stratum.  
• For both strata, the objective will be to determine if the  treatment regimen is able to be 
associated with a clinical response rate that can rule out 5% (p0=0.05) in favor of a modest 20% PR + CR rate (p1=0.20).  
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 4 TABLE OF CONTENTS  
PRÉCIS  .......................................................................................................................................... 2  
1 INTRODUCTION ................................................................................................................. 8  
1.1 Study Objectives  ................................................................................................................. 8  
1.1.1  Primary Objectives ........................................................................................................ 8  
1.1.2  Secondary Objective ..................................................................................................... 8  
1.2 Background and Rationale .................................................................................................. 8  
1.2.1  Surgery Branch Trials of Cell Transfer Therapy Using Transduction of Anti- Tumor 
Antigen TCR Genes into PBL  ...................................................................................... 8  
1.2.2  MAGE -A3 as a target for cell transfer clinical studies  ................................................. 9  
1.2.3  Rationale for Targeting a Class II Restricted Epitope of MAGE -A3 recognized by 
CD4 T Cells  ................................................................................................................ 11  
1.2.4  Safety Considerations  ................................................................................................. 14  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  .................................................. 14  
2.1 Eligibility Criteria  ............................................................................................................. 14  
2.1.1  Inclusion Criteria  ........................................................................................................ 14  
2.1.2  Exclusion Criteria  ....................................................................................................... 16  
2.2 Screening Evaluation ........................................................................................................ 16  
2.2.1  Within 3 Months Prior to Enrollment ......................................................................... 16  
2.2.2  Within 8 Weeks Prior to Enrollment:  ......................................................................... 16  
2.2.3  Within 4 Weeks Prior to Enrollment:  ......................................................................... 17  
2.2.4  Within 14 Days Prior to Enrollment:  .......................................................................... 17  
2.2.5  Within 7 Days Prior to Enrollment:  ............................................................................ 17  
2.3 Registration and Treatment Assignment Procedures  ........................................................ 17  
2.3.1  Prior to registration for this protocol  .......................................................................... 17  
2.3.2  Registration procedure ................................................................................................ 17  
2.3.3  Treatment Assignment Procedures  ............................................................................. 17  
3 STUDY IMPLEMENTATION .......................................................................................... 18  
3.1 Study Design ..................................................................................................................... 18  
3.1.1  Performed on 03-C-0277 ............................................................................................ 18  
3.1.2  Treatment Phase .......................................................................................................... 18  
3.1.3  Dose Limiting Toxicity:  .............................................................................................. 19  
3.1.4  Phase I - Dose Escalation  ............................................................................................ 19  
3.1.5  Phase 2 Portion  ........................................................................................................... 20  
3.1.6  Protocol Stopping Rules ............................................................................................. 20  
3.2 Drug Administration  ......................................................................................................... 20  
3.2.1  Preparative Regimen with Cyclophosphamide and Fludarabine ................................ 20  
3.2.2  Cell Infusion and Aldesleukin Administration: .......................................................... 21  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 5 3.2.3  Treatment Schedule .................................................................................................... 22  
3.3 On-Study Evaluations  ....................................................................................................... 23  
3.3.1  Within 14 days prior to starting the preparative regimen ........................................... 23  
3.3.2  During the preparative regimen: DAILY .................................................................... 23  
3.3.3  After Cell Infusion: ..................................................................................................... 23  
3.3.4  During Hospitalization: ............................................................................................... 23  
3.4 Retreatment  ....................................................................................................................... 24  
3.5 Post Treatment Evaluation  ................................................................................................ 24  
3.5.1  Time period of evaluations  ......................................................................................... 24  
3.5.2 24  
3.6 Criteria for Removal from Protocol Therapy and Off Study Criteria  ............................... 25  
3.6.1  Criteria for removal from protocol therapy  ................................................................ 25  
3.6.2  Off Study Criteria  ....................................................................................................... 25  
4 CONCOMITANT MEDICATIONS/MEASURES  .......................................................... 26  
4.1 Infection Prophylaxis: ....................................................................................................... 26  
4.1.1  Pneumocystis Jirovecii Pneumonia ............................................................................. 26  
4.1.2  Herpes or Varicella Zoster Virus Prophylaxis  ............................................................ 26  
4.1.3  Fungal Prophylaxis  ..................................................................................................... 26  
4.1.4  Empiric Antibiotics  ..................................................................................................... 26  
4.2 Blood Product Support ...................................................................................................... 27  
4.3 Other Concomitant medications to control side effects  .................................................... 27  
5 BIOSPECIMEN COLLECTI ON ...................................................................................... 27  
5.1 Correlative Studies for Research:  ..................................................................................... 27  
5.2 Samples Sent To Dr. Figg’s Lab ....................................................................................... 27  
5.3 Samples Sent To Surgery Branch cell Processing Laboratory  ......................................... 27  
5.3.1  Prior to chemotherapy administration:........................................................................ 28  
5.3.2  Prior to cell infusion (one 8ml SST): .......................................................................... 28  
5.3.3  Post cell infusion evaluations:  .................................................................................... 28  
5.4 Immunological Testing:  .................................................................................................... 28  
5.5 Monitoring Gene Therapy Trials: Persistence and RCR:  ................................................. 28  
5.6 Sample Storage, Tracking and Disposition For SB cell Processing laboratory ................ 29  
5.7 Sample Storage, Tracking and Disposition For Dr. Figg’s Lab ....................................... 29  
5.7.1  Sample Data Collection  .............................................................................................. 29  
5.7.2  Sample Storage and Destruction ................................................................................. 30  
6 DATA COLLECTION AND EVALUATION  .................................................................. 30  
6.1 Data Collection  ................................................................................................................. 30  
6.1.1  Exclusions to Routine Adverse Event Recording: ...................................................... 31  
6.2 Data Sharing Plan  ............................................................................................................. 31  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 6 6.2.1  Human Data Sharing Plan ........................................................................................... 31  
6.2.2  Genomic Data Sharing Plan  ........................................................................................ 32  
6.3 Response Criteria  .............................................................................................................. 32  
6.3.1  Definitions ................................................................................................................... 32  
6.3.2  Disease Parameters  ..................................................................................................... 32  
6.3.3  Methods for Evaluation of Measurable Disease  ......................................................... 33  
6.3.4  Response Criteria  ........................................................................................................ 34  
6.3.5  Confirmatory Measurement/Duration of Response .................................................... 35  
6.4 Toxicity Criteria  ................................................................................................................ 35  
7 SAFETY REPORTING REQUIREMENTS/DATA AND S AFETY MONITORING 
PLAN  .................................................................................................................................... 36  
7.1 Definitions ......................................................................................................................... 36  
7.1.1  Adverse Event  ............................................................................................................. 36  
7.1.2  Suspected adverse reaction  ......................................................................................... 36  
7.1.3  Unexpected adverse reaction  ...................................................................................... 36  
7.1.4  Serious ......................................................................................................................... 36  
7.1.5  Serious Adverse Event  ................................................................................................ 36  
7.1.6  Disability  ..................................................................................................................... 36  
7.1.7  Life-threatening adverse drug experience  ................................................................... 37  
7.1.8  Protocol Deviation (NIH Definition)  .......................................................................... 37  
7.1.9  Non-compliance (NIH Definition)  .............................................................................. 37  
7.1.10  Unanticipated  Problem................................................................................................ 37  
7.2 NCI-IRB and Clinical Director (CD) Reporting  ............................................................... 37  
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths 37  
7.2.2  NCI-IRB Requiremen ts for PI Reporting at Continuing Review ............................... 37  
7.2.3  NCI-IRB Reporting of IND Safety Reports ................................................................ 38  
7.3 IND Sponsor Reporting Criteria  ....................................................................................... 38  
7.3.1  Waivier of expedited reporting to CCR  ...................................................................... 38  
7.3.2  Reporting Pregnancy ................................................................................................... 39  
7.4 Institutional Biosafety Committee (IBC) Reporting Criteria  ............................................ 39  
7.4.1  Serious Adverse Event Reports to IBC  ....................................................................... 39  
7.4.2  Annual Reports to IBC................................................................................................ 40  
7.5 Data and Safety Monitoring Plan ...................................................................................... 40  
7.5.1  Principal Investigator/Research Team  ........................................................................ 40  
7.5.2  Sponsor Monitoring Plan ............................................................................................ 41  
7.5.3  Safety Monitoring Committee (SMC)  ........................................................................ 41  
8 STATISTICAL CONSIDERATIONS  ............................................................................... 41  
9 COLLABORATIVE AGREEMENTS  .............................................................................. 43  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 7 10 HUMAN SUBJECTS PROTECTIONS  ............................................................................ 43  
10.1  Rationale For Subject Selection  ........................................................................................ 43  
10.2  Participation of Children  ................................................................................................... 43  
10.3  Participation of Subjects Unable to Give Consent  ............................................................ 43  
10.4  Evaluation of Benefits and Risks/Discomforts  ................................................................. 44  
10.5  Risk/Benefit Analysis  ....................................................................................................... 44  
10.6  Consent Process and Documentation ................................................................................ 44  
10.6.1  Informed consent of non- English speaking subjects:  ................................................. 44  
11 PHARMACEUTICAL INFOR MATION  ......................................................................... 45  
11.1  Investigational Investigation  ............................................................................................. 45  
11.1.1  Cell Preparation (ANTI -MAGE -A3-DP4 TRANSDUCED PBL)  ............................. 45  
11.1.2  Interleukin-2 (Aldesleukin, Proleukin, Recombinant Human Interleukin 2) ............. 45  
11.1.3  Fludarabine ................................................................................................................. 46  
11.1.4  Cyclophosphamide ...................................................................................................... 47  
11.2  Supportive Medications .................................................................................................... 48  
11.2.1  Mesna .......................................................................................................................... 48  
11.2.2  Filgrastim  .................................................................................................................... 48  
11.2.3  Trimethoprim and Sulfamethoxazole Double Strength (TMP / SMX DS): ............... 48  
11.2.4  Herpes and Varicella Zoster Virus Prophylaxis .......................................................... 49  
11.2.5  Fluconazole ................................................................................................................. 50  
11.2.6  Ondansetron hydrochloride ......................................................................................... 50  
11.2.7  Furosemide .................................................................................................................. 50  
12 REFERENCES  .................................................................................................................... 51  
13 FIGURES, TABLES & AP PENDICES  ............................................................................. 56  
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 8 1 INTRODUCTION 
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objective s 
• Determine a safe dose of the administration of autologous CD4 cells transduced with an 
anti-MAGE -A3-DP0401/0402 restricted (MAGE -A3-DP4) TCR and aldesleukin to 
patients following a nonmyeloablative but lymphoid depleting prep arative regimen.  
• Determine if this approach will result in objective tumor regression in patients with 
metastatic cancer expressing MAGE -A3-DP4.  
• Determine the toxicity profile of this treatment regimen.  
1.1.2 Secondary Objective 
• Determine the in vivo survival o f TCR gene -engineered cells.  
1.2 BACKGROUND AND RATIONALE  
Studies in experimental animals have demonstrated that the cellular rather than the humoral arm 
of the immune response plays the major role in the elimination of murine tumors. Much of this evidence was  derived from studies in which the adoptive transfer of T lymphocytes from 
immune animals could transfer resistance to tumor challenge or in some experiments, the elimination of established cancer.  Thus, most strategies for the immunotherapy of patients with 
cancer have been directed at stimulating strong T cell immune reactions against tumor -associated 
antigens. 
In contrast to antibodies that recognize epitopes on intact proteins, T cells recognize short 
peptide fragments (8- 18 amino acids) that are presen ted on surface class I or II major 
histocompatibility (MHC) molecules and it has been shown that tumor antigens are presented and recognized by T cells in this fashion. The molecule that recognizes these peptide fragment s 
is the T -cell receptor (TCR).  The TCR is analogous to the antibody immunoglobulin molecule in 
that, two separate proteins (the TCR alpha and beta chains) are brought together to form the functional TCR molecule. The goal of this protocol is to transfer MAGE -A3 reactive TCR genes 
into norma l peripheral blood lymphocytes (PBL) derived from cancer patients and to return these 
engineered cells to patients aimed at mediating regression of their tumors. This trial is similar to previous Surgery Branch TCR gene transfer adoptive immunotherapy protocols that have used HLA -Class I restricted TCRs except that in this trial we will use an HLA -Class II 
(DP0401/0402) restricted TCR reactive with a MAGE -A3 epitope expressed on the tumors of 
patients with melanoma as well as patients with common epithelial malignancies.  
1.2.1 Surgery Branch Trials of Cell Transfer Therapy Using Transduction of Anti- Tumor 
Antigen TCR Genes into PBL  
We have studied approaches to transduce genes encoding antigen specific TCRs genes into PBL as a method to generate large numbers of r eactive anti -cancer T cells.  
In earlier studies we treated 24 patients with metastatic melanoma using autologous PBL transduced with high- avidity MART -1 F5 TCR following a non- myeolablative chemotherapy  
(1, 
2). Six patients (25%) achieved an objective partial response though 15 patients developed a 
transient mild anterior uveitis easily reversed by steroid eye drops and ten patients developed decreased hearing reversed by middle ear steroid injections. Transient rashes have also been 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 9 seen.  We have also conducted a clinical trial with a TCR that recognizes the gp100:154-162 
melanoma peptide(2). This TCR was raised in an HLA -A2 transgenic mouse immunized with this 
peptide. We treated 21 patients with  metastatic melanoma using autologous PBL transduced with 
this gp100 TCR following a non- myeloablative chemotherapy.  Four patients (19%) achieved an 
objective partial response. Seven patients developed a transient mild anterior uveitis reversed by 
steroid eye drops and ten patients developed decreased hearing reversed by middle ear steroid 
injections. There were no treatment related deaths in the trial. We are no longer using these 
TCRs in clinical studies.  
At the time of this protocol, w e have performed several additional studies utilizing peripheral 
blood lymphocytes transduced with either TCR or chimeric antigen receptors (CAR) genes targeting putative tumor antigens following a non -myeloablative chemotherapy regimen.  In 
protocol 08 -C-0121, 10 0f 19 pat ients (53%) with metastatic melanoma treated with autologous 
PBL genetically engineered to express an anti -NY-ESO -1 TCR experienced objective responses 
including four patients with complete responses, three of which are ongoing from 24 to 50 plus months
(3). Similarly, 15 patients with metastatic synovial cell sarcoma also received autologous 
genetically engineered cells expressing the anti- NY-ESO -1 TCR and 10 (67%) experienced 
objective regressions including one ongoing complete regression at five months(3). In study 09-
C-0082, we have recently treated 12 patients with autologous PBL transduced with genes 
encoding an anti -CD19 CAR. Four  of these patients have ongoing complete regressions from 4 
to 19 plus months and five additional patients have ongoing partial responses at 2 to 20 plus months. In both of these protocols only patients that have been heavily pre- treated with s tandard 
therapy have been admitted (early results published in 
(4, 5). 
Most toxicities observed in these studies were expected toxicities of the chemotherapy a nd 
aldesleukin a dministration. However, in 2 studies, we have observed serious adverse events 
related to the transduced cells. In 09-C-0041 (anti-Her2 CAR transduced PBL), the first patient, 
with metastatic colorectal cancer, was treated with 1010 autologous T cells trans duced with the 
retrovirus encoding an anti- Her-2 CAR. This patient developed respiratory distress and died four 
days later.  This toxicity was apparently due to a previously unrecognized ability of this CAR to 
recognize Her -2 expressed on lung epithelial ce lls although the exact explanation for the toxicity 
is not clear(6). In 09-C-0047 (anti- CEA TCR transduced PBL), all three treated  patients 
experienced diarrhea, and colitis and one patient experienced an objective response of liver metastases
(7). All gastrointestinal side effects resolved  in these patients and the patients ha ve 
normal bowel function. Grade 3 diarr hea lasting longer than 72 hours is considered a DLT per 
protocol and this event was observed in two of three patients enrolled in protocol 09-C-0047, meeting the criteria for stopping protocol accrual . 
1.2.2 MAGE -A3 as a target for cell transfer clinical studie s 
Because of our success using the anti- NY-ESO -1 TCR we have explored targeting  other cancer -
testes antigens. Cancer testis antigens (CTA)  are proteins , which are normally only expressed  in 
the placenta  and in non -MHC expressing germ cells of testis, yet are aberrantly expressed in 
many tumors; thus CTA  may represent ideal target s for tumor immunotherapy. More than 110 
CTA genes or gene families have been identified that are expressed in multiple tumor types  (8-10). 
These proteins are being vigorously pursued as targets for therapeutic cancer vaccines , and TCR 
based adoptive immunotherapy  (11-13). In theory, targeting T cells against tumor associated CT 
antigens might selectively eliminate tumor cells while avoiding toxicity to normal tissue.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 10 Since the identification of the first human MAGE CT gene in 1991, the number of MAGE family 
genes has  grown to over 25 members  (14, 15). MAGE -A is a multigene family consisting of 12 
homolog ous genes , MAGE -A1 to A12 located at chromosome Xq28(10). Genomic clustering, 
restricted expres sion pattern and single exon open reading frame s of the MAGE genes are 
consistent with the possibility that these genes evolved from retrotransposition and subsequent duplication
(16). The precise function and biological role of MAGE proteins are not completely 
elucidated. However, members of MAGE-A, B and C proteins have been implicated in the suppression of p53-dependent apoptos is 
(17, 18) and MAGE -A3 has been attributed to mediate 
fibronectin -controlled tumor progression and metastasis(19). Expression of CTAs including 
MAGE genes in tumor cells has been attributed to global DNA de methylation and other 
mech anisms that normally silences these genes in somatic cells(20). MAGE -A3 is one of the more 
frequently expressed CT antigen s in human tumors, including melanoma(21), non -small cell lung 
carcinoma(22), head and neck squamous cell carcinoma(23), pancreatic cancer(24), hepatocellular 
carcinoma(25), non- Hodgkin lymphoma(26), and multiple myeloma(27). The expression of MAGE -
A3 has been shown to be higher in more advanced stages of disease, and is associated with poor disease prognosis 
(28-30). Several antigenic peptides that bind to HLA class I or class II molecules  
on tumor cells  have been  reported  (31-37). Because of its high expression in a wide array of tumor 
types, MAGE -A3 was chosen as the target for cancer immunotherapy.  
A high avidity Class I restricted TCR against MAGE -A3 was isolated  using a transgenic mouse 
model that expresse d the human HLA -A*0201 molecule. A retrovirus encoding the alpha and 
beta chains of this TCR that recognized the Class I restricted MAGE -A3 epitope (aa112 -120) 
was constructed. Nine cancer patients were treated with adoptive cell t herapy using autologous 
anti-MAGE -A3 T -cell receptor (TCR) engineered T cells.  Five patients experienced clinical 
regression of their cancers including 2 on-going responders. However, postinfusion, 3 patients experienced mental status changes, and 2 patien ts lapsed into comas and subsequently died
(38). 
The TCR used in this study recognized epitopes in MAGE-A3/A9/A12. Molecular assays of 
human brain samples using real- time quantitative -polymerase chain reaction, Nanostring 
quantitation, and deep- sequencing indicated that MAGE -A12 was expressed in human brain and 
our TCR recognized an epitope in MAGE- A12 that was similar to the MAGE -A3 epitope being 
targeted. This previously unrecognized expression of MAGE-A12 in human brain was possibly the initiating event of a TCR -mediated inflammatory response that resulted in neuronal cell 
destruction. There was no evidence of MAGE -A3 expressed in the brain. In a protocol using a 
TCR that recognized HLA- A1 Class I restricted epitope from MAGE -A3, cardiac toxicity was 
seen that was attributed to changes introduced into the binding regions of the
(39) TCR , which 
added new specificities resulting in cardiac rejection . These changes were thought to be the 
cause of the off target toxicity.  This study will use an unmodified human receptor and thus we do 
not expect to see the same off target toxicities.  
However , other MAGE -A3 epitopes may be good candidate s for tumor immunotherapy because 
of the high percentage of tumors that express MAGE genes, (for example >60% of melanomas and >50% of NSCLC) and large numbers of patients can be eligible for treatment. Finally 
MAGE -A3 has not been found to be expressed in any normal tissue except testis  and this may 
limit the risk of on -target toxicity to normal tissue.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 11 1.2.3 Rationale for Targeting a Cl ass II Restricted Epitope of MAGE -A3 recognized by CD4 T 
Cells  
The ability of CD8+ T cells that have been genetically modified to express TCRs that recognize 
HLA class I restricted antigens to mediate tumor regression has now been demonstrated in a 
series of clinical trials that target  the melanocyte differentiation antigens (MDAs) MART -1 and 
gp100 (38, 40), as well as the cancer germ -line antigens MAGE -A3(2) and NY- ESO -1(3). 
Nevertheless, durable complete tumor regressions were observed in only a relatively small percentage of patients treated in these trials. Multiple factors may be respo nsible for the lack of 
durable responses seen in these patients, including insufficient persistence of transferred cells, heterogeneity of antigen and HLA class I expression, as well as the presence of host factors that suppress the response of adoptively transferred T cells. In addition, CD4
+ T helper cells have 
been found to play a role in mediating anti-tumor immunity in murine tumor model systems, raising the possibility that lack of sufficient T cell help may impair the effectiveness of human therapies that have focused on the use of class I restricted TCRs. Tumor -reactive CD4
+ T cells 
that recognize the murine leukemia virus epitopes (41, 42) as well as the TRP -1 melanocyte 
differentiation antigen(43) have been shown to be effective in mediating the regression of 
established murine tumors. Additional findings indicate that CD4+ T cells can enhance and 
maintain in vivo  responses of tumor -reactive CD8+ T cells(44, 45). 
A variety of HLA class II restricted antigens expressed on human tumor cells have been identified, providing an opportunity to evaluate the effectiveness of CD4+ T cells in mediating tumor regression in patients. Multiple epitopes derived from MDAs, including MART-1
(46), 
tyrosinase(47), gp100 (47-49) and TRP-1 (50, 51) have been shown to be recognized by human CD4+ 
tumor reactive T cells. In addition, HLA class II restricted epitopes derived from multiple cancer germ -line gene products, including MA GE-A3 
(32, 34, 52, 53), MAGE -A1(54), NY -ESO -1 (55, 56), 
SSX-2(57) and SSX -4(58), have been identified by stimulating T cells in vitro  with either 
recombinant proteins or peptides derived from these products. In the only clinical trial to specifically target an HLA class II restricted antigen, an autologous  CD4
+ T cell clone that 
recognized an HLA -DP*04 -restricted epitope of NY -ESO -1 mediated tumor regression in a 
patient with melanoma(59). This finding provided an impetus to further investigate the role of 
CD4+ tumor reactive T cells in mediating tu mor regression.  
We thus focused on the isolation of class II restricted TCRs directed against the MAGE -A3 
cancer germ -line antigens  which is expressed in a variety of tumor histologies  (60, 61). In previous 
studies aimed at identifying HLA class II restricted MAGE -A3 T cell epitopes, PBMC were 
stimulated  with autologous dendritic cells (DCs) that had been pulsed with recombinant MAGE-
A3 protein(34). A single CD4+ T cell clone was identified in this study, clone 22, that r ecognized 
autologous EBV B cells that were either pulsed with recombinant MAGE-A3 protein or transduced with a recombinant retroviral construct encoding the MAGE-A3 protein. Further analysis lead to the identification of a peptide corresponding to a mino ac ids 243-258 of the 
MAGE -A3 protein, KKLLTQHFVQENYLEY (MAGE -A3:243-258), that was recognized in 
association with two HLA class II allele DP β1 alleles, *0401 and *0402. The DP β1*0401 allele 
is expressed by approximately 70% of Caucasians, whereas the closely  related DP β1*0402 
allele, which differs from the 0401 allele by four amino acids, is expressed by approximately 20% of Caucasians. Further analysis indicated that the minimal epitope recognized by clone 22 corresponded to the 12- mer TQHFVQENYLEY (MAGE -A3:247- 258). Targets cells expressing 
DPβ1*0401 that were either pulsed with the MAGE-A3:247-258 peptide or transduced with the 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 12 MAGE -A3 gene were strongly recognized by clone 22, whereas targets expressing the 
DPβ1*0402 allele were recognized to a lower but nevertheless significant extent. Subsequently, 
a patient clinical trial was carried out involving immunization of patients with MAGE -A3 
protein in combination with a group of HLA class I and class II restricted peptides that included 
the MAGE -A3:243- 258 HLA -DPβ1*04 restricted peptide that were selected on the basis of the 
patients’ HLA haplotype(62). Although objective responses were not observed in this trial, 
subsequent in vitro  studies were carried out to evaluate the phenotype and function of T cell 
clones from HLA- DPβ1*0401 or 0402+ patients that were isolated from the peripheral blood of 
immunized patients using a HLA-DP*04 tetramer containing the MAGE-A3:243-258 peptide. 
This procedure lead to the isolation of CD4+ MAGE -A3:243- 258 reactive T effector clones that 
released IFN -γ and TNF -α following antigen stimulation, as well as T cell clones that appeared 
to represent CD4+ regulatory T cells (CD4+ Tregs) that recognized the same T cell epitope. 
These MAGE -A3 reactive CD4+ Treg clones failed to release effector cytokines fo llowing 
specific antigen stimulation, but were capable of suppressing effector T cell responses in response to stimulation with the MAGE -A3:243-258 peptide. 
Given the high prevalence of the HLA -DP*04 HLA class II allele in the patient population, as 
well a s the high frequency of MAGE- A3+ tumors in patients with melanoma as well as other 
malignancies, we attempted to identify potent TCRs directed against the MAGE -A3:243-258 
HLA -DP*04 restricted epitope. Initially, we isolated the endogenous TCR alpha and bet a chains 
expressed by two of the MAGE-A3:243-258- reactive effector CD4+ T cell clones, clones R12C9 
and 12C7, as well as a CD4+ Treg clone reactive with this epitope, each of which was 
characterized in the MAGE -A3 cancer vaccine trial study described above (kindly provided by 
Dr. Pierre van der Bruggen). Following the cloning of t he TCR alpha and beta chains isolated 
from the three MAGE- A3 reactive clones they were then joined with the P2A self -cleaving 
peptide sequence and cloned in the MSGV1 retroviral vector. Three patient PBMC that had been stimulated with OKT3 were then transduced with transient retroviral supernatants on day two and enriched for CD4
+ T cells on day seven, and assayed for their ability to recognize target cells 
on day 12. Analysis of the levels of transduction carried out by staining transduced cells with 
anti-Vβ22, Vβ6.7 and V β12 which detect the 6F9, R12C9 and 12A7 TCR (all kindly provided 
by Dr. Pierre van der Bruggen) indicated that the levels of transduction were similar, ranging 
between 25 and 35% ( Figure 1a). The results of co- culture assays indicated that T cells 
transduced with either the 6F9, R12C9 or the 12C7 TCR strongly recognized HLA -DP*0401+ 
target cells pulsed with the MAGE-A3:243-258 peptide ( Figure 1b). In contrast, CD4+ T cells 
transduced with the 6F9 but not the R12C9 or 12C7 TCRs recogni zed HLA DP*0401+ 293-
CIITA cells transfected with genes encoding MAGE -A3 or MAGE -A6, but not MAGE- A1 or 
A12 ( Figure 1b). Comparison of amino acid sequences of the corresponding regions of the 
MAGE family members indicated that MAGE -A3 and MAGE -A6 only differed at one position 
(residue 249), whereas the other MAGE family members differed from MAGE-A3 at 2 (MAGE-A12) or 3 (MAGE -A1) positions ( Table 1 a). In addition, CD4
+ T cells transduced with the 6F9 
TCR but not the R12C9 or 12C7 TCRs recognized the MAGE- A3+/HLA -DP*0401+ melanoma 
cell line 1359 mel-CIITA but failed to recognize the MAGE -A3+/HLA -DP*0401- melanoma cell 
line 624 mel- CIITA. CD4+ T cells transduced with the R12C9 TCR failed to recognize either of 
the tested melanoma cell lines, whereas cells transduced with th e 12C7 TCR weakly recognized 
624 mel -CIITA but not 1359 mel- CIITA cells (Figure 1b).  Titration of the MAGE -A3:243-258 
peptide indicated that CD4+ T cells transduced wi th the 6F9 and R12C9 TCRs released 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 13 comparable levels of IFN -γ in response to targets pulsed with a minimum of between 0.001 and 
0.01 mg/m L of the MAGE -A3:243-258 peptide, whereas cells transduced with the 12C7 TCR 
appeared to release significantly less IFN -γ than those transduced with the other two TCRs 
(Figure 1c).  These results indicated that while CD4+ T cells transduced with any of the three 
MAGE -A3 reactive TCRs 6 F9, R12C9 and 12C7 TCR recognized peptide pulsed target cells, 
only cells transduced with the 6F9 TCR recognized transfected target cells as well as MAGE-
A3+ and HLA -DP*04+ tumor cells.  
The 6F9 TCR was further evaluated by determining the reactivity of CD4+ and CD8+ T cells 
separated from two patient PBMCs against a panel of tumor cell lines. Five melanoma cell lines that expressed MAGE -A3 and HLA-DP*0401, as well as the non- small cell lung carcinoma cell 
line H1299 NSCLC -CIITA were recognized by transduced  CD4
+ and CD8+ T cells, although 
CD4+ T cells secreted higher amounts of cytokine in response to tumor targets than transduced 
CD8+ T cells ( Figure 2A ). Prior studies have demonstrated higher reactivity of human TCRs in 
which sequences encoding the human TCR alpha and beta chain constant regions had been replaced with those encoding the corresponding murine constant regions
(63). The effect s of 
replacing the constant regions of the 6F9 TCR alpha and beta chains with murine sequences was then evaluated by constructing a retroviral vector encoding the murine constant regions, designated 6F9mc. Comparisons of responses of CD4+ T cells transduced with the normal 6F9 TCR with those transduced with the 6F9mc TCR indicated that the murine constant regions resulted in between two and five- fold enhancement in the response of transduced T cells against 
the seven MAGE -A3
+ and HLA -DP*0401+ targets that w ere evaluated ( Figure 2B ). In addition, 
the response of CD8+ T cells transduced with the 6F9mc were enhanced by between two and ten -
fold above those seen in cells transduced with the native 6F9 TCR. The responses of CD8+ T 
cells transduced with the 6F9mc were generally lower than CD4+ T cells transduced with this 
TCR, although comparable cytokine responses were observed in responses to some tumor targets (Figure 2C ). 
In order to evaluate the fine specificity of antigen recognition mediated by cells transduced with the 6F9 and 6F9mc TCR, HLA-DP*0401
+ target cells were pulsed with truncations of the 
MAGE -A3:243-258 peptide and related peptides from MAGE family members. Analysis of the 
response to truncated MAGE-A3 peptides from two cultures of transduced CD4+ PBMC 
indicated that the 11-mer peptide QHFVQENYLEY corresponding to amino acids 248-258 of the MAGE -A3 protei n represented the minimal peptide that elicited a response comparable to 
that elicited by the MAGE -A3:243-258 peptide ( Table 1B ) that was nearly identical to the 
minimal epitope that was previously described but that lacked the amino terminal threonine residue present in that peptide
(34). The MAGE -A3:243-258 peptide was predicted using an 
epitope prediction algorithm to possess a high affinity for HLA-DP*0401, and in addition, recognition of the truncated MAGE -A3 peptides appeared to correlate with T cell recognition 
(
Table 1B ). Significant recognition of the MAGE-A6:248-258 peptide that contained a single 
substitution of tyrosine for histidine at position 249, was seen  but minimal reactivity was 
observed against additional members of the MAGE family of gene products that possessed between two and five differences from the MAGE-A3:248- 258 peptide. A BLAST search of the 
NCBI database revealed that the most closely related peptide in the human genome was derived 
from the protein necdin. This peptide, which possessed five differences from the MAGE -
A3:248-258 peptide, was also not recognized by T cells transduced with the 6F9 or 6F9mc TCR. These findings indicate that the 6F9 TCR possesses a high degree of specificity for the MAGE-
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 14 A3:248- 258 peptide and suggest that T cells transduced with this TCR may possess little or no 
cross -reactivity with peptides derived from additional human proteins. 
To evaluate the anti -MAGE -A3 DP4 TCR at clinical scale, CliniMACs clinical- scale cell 
separation apparatus was used to deplete CD8+ lymphocytes fr om PBL. CD8- depleted PBL were 
stimulated for 2 days with OKT -3 antibody and then transduced twice by anti- MAGE -A3 DP4 
TCR retrovirus. Flow cytometric analysis of transduced PBL showed that 92.0% of CD4+ T cells 
were transduced with this TCR vector, detected by anti- mouse TCR β antibody ( Figure 3). In 
addition, 96.1% of transduced PBL were CD4+ T cells, with less than 0.1% CD8+ T cells. To 
assess the speci fic recognition of tumor cells, TCR -engineered CD4+ T cells were co -cultured 
with HLA -DP0401+ MAGE -A3+ target cells  or M AGE-A3 peptide -pulsed cells . High levels of 
IFN-γ were observe d from the co- culture wells with specific target cells  but not negative controls 
(Figure 4A ). Furthermore, TCR-engineered CD4+ T cells  were  rapidly expanded one time to 
achieve sufficient cell numbers for  patient infusion , and the same biological assays were 
performed. Similar results were obtained, with 92.6% of transduced T cells and 99.2% of CD4+ 
T cells ( Figure 3). Specific release of IFN -γ from  TCR -engineered CD4+ T cells  was also 
observed  (Figure 4B ). 
1.2.4 Safety  Considerations  
Several safety concerns regarding the infusion of large numbers of retrovirally modified tumor 
reactive T -cells have been addressed in our previous clinical studies as described below. The 
non-myeloablative chemotherapy  and the administration of high- dose aldesleukin  have expected 
toxicities which are discussed in Section 6 of this study . The non myeloablative chemotherapy 
used in this protocol has been administered to over 300 patients and all have reconstituted their hematopoietic systems.  
In other protocols we have administered over 3 X 10
11 TIL with widely heterogeneous 
reactivity including CD4, CD8, and NK cells without difficulty.  We do not believe the 
transfer of these gene modified cells has a significant risk for malignant transformation in this patient population. While the risk of insertional mutagenesis is a known possibility using retroviral vectors,  this has only been observed in the setting of infants treated for 
XSCID , WAS and X -CGD  using retroviral vector -mediated gene transfer into CD34+ 
bone marrow cells.  In the case of retroviral vector -mediated gene transfer into mature T -
cells, there has been  no evidence of long -term toxicities associated with these procedures 
since the first NCI sponsored gene transfer study in 1989. Although continued follow-up of all gene therapy patients will be required, data suggest that the introduction of retroviral ve ctors transduced into mature T -cells is a safe procedure.  While we believe the 
risk of insertional mutagenesis is extremely low, the proposed protocol follows all current FDA guidelines regarding testing and follow up of patients receiving gene transduced cells.  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT   
2.1 E
LIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria  
a. Metastatic  or locally advanced refractory/recurrent  cancer that expresses MAGE -A3 
as assessed by one of the following methods:  RT-PCR on tumor tissue  defined as 
30,000 copies of MAGE -A3 per 106 GAPDH copies , or by immunohistochemistry of 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 15 resected tissue defined as 10% or greater of tumor cells being 2-3+ for MAGE -A3, or 
serum antibody reactive with MAGE -A3. Metastatic cancer diagnosis will be 
confirmed by the Laboratory of Pathology at the NCI.  
b. Patients must have previously received prior first line standard therapy  (or effective 
salvage chemotherapy regimens) for their disease, if known to be effective for that 
disease, and have been either non-responders (progressive di sease) or have recurred . 
c. Patients must be HLA- DP4 positive . 
d. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and 
asymptomatic are eligible.  Lesions that have been treated with stereotactic radiosurgery 
must be clinically stable  for 1 month after treatment for the patient to be eligible. 
Patients with surgically resected brain metastases are eligible.  
e. Greater than or equal to 18 years of age and less than or equal to age 70. 
f. Ability of subject to understand and the willingness to  sign the Informed Consent 
Document 
g. Willing to sign a durable power of attorney 
h. Clinical performance status of ECOG 0 or 1  
i. Patients of both genders must be willing to practice birth control from the time of 
enrollment on this study and for up to four month s after treatment. 
j. Serology:  
• Seronegative for HIV antibody.  (The experimental treatment being evaluated in 
this protocol depends on an intact immune system. Patients who are HIV 
seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)  
• Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody . If 
hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT- PCR and be HCV RNA negative.   
k. Women of child- bearing potential must have a negative pregnancy test because of the 
potentially dangerous effects of the treat ment  on the fetus.   
l. Hematology 
• Absolute neutrophil count greater than 1000/mm
3 without the support of 
filgrastim  
• WBC ≥ 3000/mm3 
• Platelet count ≥ 100,000/mm3 
• Hemoglobin > 8.0 g/dL 
m. Chemistry:  
• Serum ALT/AST ≤ to 2.5 times the upper limit of normal  
• Serum c reatinine ≤ to 1.6 mg/dL 
• Total bilirubin ≤ to 1.5 mg/d L, except in patients with Gilbert’s Syndrome who 
must have a total bilirubin less than 3.0 mg/dL. 
n.More than four weeks must have elapsed since any prior systemic therapy at the time the 
patient receive s the preparative regimen, and patients’ toxicities must have recovered to 
a grade 1 or less (except for toxicities such as alopecia or vitiligo).  Patients must have 
progressing disease after prior treatment . Note:  Patients who have previously received 
ipilimumab and have documented GI toxicity must have a normal colonoscopy with 
normal colonic biopsies. 
o.Subjects must be co -enrolled in protocol 03-C-0277. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 16  
2.1.2 Exclusion Criteria  
a. Women of child-bearing potential who are pregnant or breastfeeding because of the 
potentially dangerous effects of the treatment  on the fetus or infant. 
b. Active systemic infections  (e.g.: requiring anti -infective treatment) , coagulation disorders 
or any other active major medical illnesses.  
c. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency 
Disease).  
d. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).  
e. Concurrent systemic steroid therapy.  
f. History of severe immediate hypersensitivity reaction to any of the agents used in this study.  
g. History of any cardiac events including coronary revascularizat ion or ischemic 
symptoms. 
h. Documented LVEF of less than or equal to 45% testing is required in patients who are  
• ≥ 65 years’  old 
• Clinically significant atrial and or ventricular arrhythmias including but not 
limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart 
block or have a history of ischemic heart disease, or chest pain.  
i. Documented FEV1 less than or equal to 60% predicted tested in patients with: 
• A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years ). 
• Symptoms of respiratory dysfunction 
j. Patients who are receiving any other investigational agents.  
2.2 S
CREENING EVALUATION  
Note: Testing for screening evaluation is conducted under our companion protocol, 99-C-0128. 
2.2.1 Within 3 M onths Prior to Enrollment 
a) HIV antibody titer and HBsAg determination, anti HCV (may be performed within 3 
months of chemotherapy start date). 
b) Confirmation of HLA -DP4 positivity. (Note: Testing is perm itted to be conducted at any 
time prior to enrollment.) 
c) Confirmation of the diagnosis of cancer and MAGE A3 by the Laboratory of Pathology of the NCI. (Note: Testing is permitted to be conducted at any time prior to enrollment.)  
2.2.2 Within 8 W eeks Prior to Enrollment:  
a) Pulmonary Function testing for patients with a prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years) or symptoms of respiratory dysfunction.  
b) Cardiac Evaluation (stress thallium, echocardiogram, MUGA etc.,) for pat ients who are 
greater than or equal to age 60, or have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, heart block.  Patients with a LEVF of less than 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 17 or equal to 45% will not be eligible. Patients under the age of 60 who have cardiac risk 
factors may also undergo cardiac evaluation as noted above (e.g., diabetes, hypertension, 
obesity).  
2.2.3 Within 4 W eeks Prior to Enrollm ent:  
a. Complete history and physical examination, including weight, vital signs , and noting in 
organ system involvement and any allergies/sensitivities to antibiotics . (Note : patient 
history may be obtained within 8 weeks.) 
b. Baseline imaging to determine the status of disease.  This may include CT, MRI, PET, or 
photography.  
2.2.4 Within 14 D ays P rior to Enrollment: 
a. Screening  blood tests :  
• Chemistries: Creatinine, ALT/GPT, AST/GOT, and Total Bilirubin  
• CBC with differential and platelet count 
b. Urinalysis ; urine cultu re, if indicated  
2.2.5  Within 7 D ays P rior to Enrollment: 
• β-HCG pregnancy test (serum or urine) on all women of child-bearing potential 
• ECOG performance status of 0 or 1  
2.3  REGISTRATION AND TREATMENT ASSIGNMENT PROCEDURES  
2.3.1 Prior to registration for this  protocol  
Patients will initially be registered on protocol 03-C-0277 (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols) prior to transduction of PBL cells (either fresh or cryopreserved samples) , by the clinical fellow or re search nurse.  
Once cells exceed the potency requirement and are projected to exceed the minimum number specified in the Certificate of Analysis (COA) , patients will sign the consent document for this 
protocol . 
2.3.2 Registration procedure 
Authorized staff must register an eligible candidate with NCI Central Registration Office (CRO) 
within 24 hours of signing consent. A registration Eligibility Checklist from the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to: NCI Central Registration Office ncicentralregistration -l@mail.nih.gov. After 
confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the acceptance of the patient on the protocol . Verification of Registration will be 
forwarded electronically via e- mail to the research team. A recorder is available during non -
working ho urs.  
2.3.3 Treatment Assignment Procedures  
Cohorts 
Number  Name  Description  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 18 1 MAGE -A3 (Phase 1) MAGE -A3-expressing metastatic or locally advanced 
refractory/recurrent cancer  
2 Melanoma (Phase 2, 
Cohort I)   Metastatic melanoma  
3 Renal and Other (Phase 2, Cohort 2)  Renal cancer and other types of metastatic cancer  
Arms  
Number  Name  Description  
1 Phase 1 Experimental Therapy  Non-myeloablative lymphodepleting preparative 
regimen of cyclophosphamide and fludarabine + Anti-MAGE -A3-DP4 TCR PBL + high- dose aldesleukin  
2 Phase 2 Experimental Therapy  Non-myeloablative lymphodepleting preparative 
regimen of cyclophosphamide and fluda rabine + Anti -
MAGE -A3-DP4 TCR PBL + high- dose aldesleukin  
Cohort and Arm Assignment  
• Subjects in Cohort 1 will be directly assigned to Arm 1.  
• Subjects in Cohort 2 will either be assigned to Arm 1 or Arm 2.  
3 STUDY IMPLEMENTATION 
3.1 STUDY DESIGN  
3.1.1 Performed on 03-C-0277 
PBMC will be obtained by leukapheresis (approximately 1 X 1010 cells).  CD4+ cells will be 
enriched on Miltenyi columns as described in the IND and cultured in the presence of anti -CD3 
(OKT3) and aldesleukin in order to stimulate T-cell growth. Tr ansduction is initiated by 
exposure of approximately 1 X 107 to 5 X 108 cells to supernatant containing the an ti-MAGE -
DP4 retroviral vector. The CD4 enriched cells will then be further expanded in vitro prior to cell infusion.  Successful TCR gene transfer will be determined by FACS analysis for the TCR 
protein and anti- tumor reactivity will be tested by cytokine release as measured on peptide 
pulsed DP4
+ cells.  Successful TCR gene transfer for each transduced PBL population will be 
defined as >10% TCR posit ive cells and for biological activity, gamma -interferon secretion must 
be at least 200pg/ml, and > 2 times background. 
3.1.2 Treatment Phase 
Patients will receive no other experimental agents while on this protocol.  Patients will receive 
the standard NCI Surgery  Branch non- myeloablative, lymphodepleting preparative  regimen 
consisting of cyclophosphamide and fludarabine followed by IV infusion  of anti -MAGE -A3-
DP4 TCR  engineered PBL and aldesleukin. All patients will receive one course of  treatment . The 
start date of the course will be the start date of the chemotherapy; the end date will be the day of 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 19 the first post-treatment evaluation. Patients may undergo a second treatment as  described in 
Section 3.3. 
3.1.3 Dose Limiting Toxicity:  
Dose -limiting toxicity is defined as follows: All grade 3 and greater  toxicities with the exception 
of: 
• Myelosuppression, defined as lymphopenia, neutropenia , decreas ed hemoglobin,  and 
thrombocytopenia.  
• Aldesleukin expected toxicities as defined in Appendix 2 and Appendix 3. 
• Expected chemotherapy toxicities as defined in the Pharmaceutical Information section.  
• Immediate hypersensitivity reactions occurring within 2 hours of cell infusion (related to cell 
infusio n) that are reversible to a grade 2 or less within 24 hours of cell administration with 
standard therapy . 
• Grade 3 Fever   
• Grade 3 Metabolic Laboratory abnormalities without significant clinical sequela that resolve 
to grade 2 within 7 days 
• Grade 3 autoimmun ity, that resolves to less than or equal to a grade 2 autoimmune toxicity 
within 10 days 
Patients who develop toxicity due to study agents will be followed until toxicity resolves to grade 2 or less, regardless of disease progression. 
3.1.4 Phase I - Dose Escalation  
Initially, the protocol will enroll 1 patient in each dose level unless a patient experiences  a dose 
limiting toxicity  (DLT ). The total number of anti- MAGE - A3-DP4 engineered PBL cells 
transferred for each dose level will b e: 
 
Dose Level  Dose  
Level 1  1.0 x 107 cells  
Level 2  3.0 x 107 cells  
Level 3 1.0 x 108 cells  
Level 4 3.0 x 108 cells  
Level 5 1.0 x 109 cells 
Level 6 3.0 x 109 cells  
Level 7 1.0 x 1010 cells  
Level 8  3.0 x 1010 cells 
Level 9  1.0 x 1011 cells  and up to 2.0 x 1011 cells  
 
In each dose level , if a patient experiences a DLT, a total of six patients will be treated at  that 
dose to confirm that no greater than 1/6 patients have a DLT  prior to proce eding to the next 
higher dose level. If a dose level with 2 or more DLTs in 3 -6 patients has been identified, 
patients will be accrued at  the next -lowest dose level , for a total of 6 . If a dose limiting toxicity 
occurs in the first dose level , that dose level  will be expanded to n=6 patients. If two DLTs occur 
in the first dose level , the study may be amended to treat patients at lower doses.  If escalation is 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 20 permitted until D ose L evel 9, it will be expanded to 6 patients unless it has 2 or more with DLTs 
before the 6th patient has been evaluated.  
The maximum tolerated cell dose is the highest dose at which  < 1 of 6 patients experienced a 
DLT or the highest dose level studied if DLTs are not observed at any of the dose levels . 
A two -week  safety assessment period following cell administration will be con ducted between 
each dose level and before enrollment into the phase 2 portion of the protocol. 
3.1.5 Phase 2 Portion  
Similar to the Phase 1 portion, prior to receiving the engineered PBL cells, patients in the phase 
2 portion will receive a nonmyeloablative but lymphocyte depleting preparative regimen 
consisting of cyclophosphamide and fludarabine followed in one to four days by intravenous infusion of MAGE -A3-DP4 TCR transduced PBL.  
The phase 2 portion of the protocol will proceed using from  10
9 cells up to the MTD as 
determined in the phase 1 portion of the study . 
In the phase 2 portion of this study, patients will be entered into two cohorts based on histology: cohort 1 will include patients with metastatic melanoma; cohort 2 will include p atients with renal 
cancer and other ty pes of metastatic cancer.  
3.1.6 Protocol Stopping Rules 
New subject enrollment to the protocol will be temporarily halted if any of the following conditions are met, and discussions will be had with the FDA or NIH IRB regarding protocol revisions if applicable : 
• If 1 or more treatment related death occur due to the cell infusion,  we will promptly 
discuss this with the NIH  IRB and the FDA.  
• During the phase 1 portion of the study – if two or more patients develop a grade 3 or 
greater toxicity related  to the cell product, with the exception of : 
•  Grade 3 metabolic laboratory abnormalities without significant clinical 
sequela that resolve to grade 2 or less within 7 days.   
• Grade 3 fever  
• If one  of the first three patients (or 2 of the first 6 patients, or 3 of the first 9 patients, or 4 
of the first 1 2 patients) develop grade 3 autoimmunity, that cannot be resolved to less 
than or equal to a grade 2 autoimmune toxicity within 10 days, or any grade 4 or greater autoimmune toxicity . 
• During the phase 2 portion of the study - Once five or more patients hav e been enrolled, 
and if 20% or more patients cumulatively enrolled have  developed a DLT, as described 
in Section 3.1.1. 
3.2 D
RUG ADMINISTRATION  
3.2.1 Preparative Regimen with Cyclophosphamide and Fludarabine 
(Starting on day -6, study medication start times for drugs given once daily should be given within 2 hours of the scheduled time. Chemotherapy infusions maybe slowed or delayed as 
medically indicated. Administration of diuretics, electrolyte replacement, and hydration and 
monitoring of electrolytes should all be performed as clinically indicated.) 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 21 DAYS -7 and -6  
Approximately 6 hours Prior to Cyclophosphamide Hydrate: Begin hydration with 0.9% Sodium Chloride Injection containing 10 meq/L of 
potassium chloride at 1.5 - 2.6 ml/kg/hr (starting approximately 6 hours’  pre-cyclophosphamide 
and continue hydration until 24 hours after last cyclophosphamide infusion). At any time during the preparative regimen, i f urine output <1 ml/kg/hr or if body weight >2 kg over pre-
cyclophosphamide value, furosemide 10- 20 mg IV maybe  administered. The hydration rate will 
be capped at 250mL/hr. 
Approximately 1 hour pre-Cyclophosphamide Ondansetron (0.15 mg/kg/dose [rounded to the nearest even mg dose between 8 mg and 16 mg 
based on patient weight] IV every 8 hours X 3 days) will be given for nausea.  
Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 
days over 1 hr. If patient is obese (BMI > 35) drug dosage will be calculated using practical weight as described in A ppendix 1.  
A decreased dose of cyclophosphamide at 30mg/kg/day (x2 days) will be considered for patients who have a history of prolonged hematologic recovery from prior chemotherapy treatm ents. 
Immediately following the end of Cyclophosphamide 
Begin mesna infusion at 3 mg/kg/hour intravenously diluted in a suitable diluent (see 
pharmaceutical section) over 23 hours after each cyclophosphamide dose. If patient is obese (BMI > 35) drug dosage will be calculated using practical weight as described  in Appendix 1.  
DAYS -7 to -3 
Fludarabine 25 mg/m
2/day IVPB daily over 30 minutes for 5 days. If patient is obese (BMI > 35) 
drug dosage will be calculated using practical weight as described in Appendix 1. (The 
fludarabine will be started approximately 1-2 hours after the cyclophosphamide and mesna on Days -7 and - 6)  
3.2.2 Cell Infusion  and Aldesleukin Administration:  
The patient’s PBL is delivered to the patient care unit by a staff member from the Tumor 
Immunolo gy Cell Processing Laboratory . Prior to infusion, the cell product identity label is 
double-checked by two authorized staff (MD or RN), an identification of the product and docume ntation of administration are entered in the patient’s chart, as is done for blood banking 
protocols.  The cell dose will be given over 20-30 minutes or as clinically determined by an 
investigator for patient safety via non -filtered tubing, gently agitating the bag during infusion to 
prevent cell clumping. 
Aldesleukin will be administered at a dose of 720,000 IU/kg (based on total body weight) as an 
intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusi on and continuing for up to 5 days (maximum 15 doses). Doses will be 
preferentially administered every eight hours; however, up to 24 hours may elapse between doses depending on patient tolerance. Aldesleukin dosing will be stopped if toxicities are not sufficiently recovered by supportive measures within 24 hours of the last dose of aldesleukin. 
Doses will be delayed or stopped if patients reach Grade 3 or 4 toxicity due to aldesleukin except for the reversible Grade 3 toxicities common to aldesleukin such as diarrhea, nausea, vomiting, 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 22 hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and 
laboratory changes as detailed in Appendix 2. Toxicities will be managed as outlined in 
Appendix 3. In addition, dosing may be held or stopped at the discretion of the treating investigator.  (Appendix 4 lists the toxicities seen in patients treated with aldesleukin at the NIH 
Clinical Center). Because confusion is a possible s ide effect of aldesleukin administration, a 
Durable Power of Attorney will be signed by the patient to identify a surrogate to make decisions if a patient becomes unable to make decisions.  
DAY 0 (one to four days after the last dose of fludarabine):  
• Cells  will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes or 
as clinically determined by an investigator for patient safety  via non -filtered tubing, gently 
agitating the bag during infusion to prevent cell clumping.  
• Aldesleukin as described above . 
DAY 0-4 (Day 0 is the day of cell infusion):  
• Beginning on day 1 or 2, filgrastim may be administered subcutaneously at a dose of 5 
mcg/kg/day (not to exceed 300 mcg/day). Filgrastim administration will continue daily until neutrophil count > 1.0 x10
9/L X 3 days or > 5.0 x109/L.  
• Aldesleukin as described above . 
3.2.3 Treatment Schedule 
1One to four days after the last dose of fludarabine  
2Initiate within approximately 24 hours after cell infusion  
3Continue until neutrophils count > 1X109/L for 3 consecutive days or > 5x109/L. Day -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 
Therapy              
Cyclophosphamide (60 mg/kg) X X           
Fludarabine (25 mg/m2) X X X X X        
Anti- MAGE -A3-DP4 TCR PBL         X1     
Aldesleukin        X2 X X X X 
Filgrastim3 (5 mcg/kg/day)         X X X X 
TMP/SMX4 
160mg/800 mg (example)         X  X  X 
Fluconazole5 (400 mg po)        X X X X X 
Valacyclovir po or Acyclovir IV6        X X X X X 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 23 4The TMP/SMX schedule should be adjusted to QD three times per week (Monday, Wednesday, Friday) 
and continue for at least six months and until CD4 > 200 X 2, starting day 0 or within one week of 
anticipated lymphopenia  
5Continue until ANC > 1000/mm3 
6In patients positive for HSV or VZV continue until  CD4 > 200 X 2 
3.3 ON-STUDY  EVALUATIONS  
Note:  Please refer to section 5 for research evaluations.  
3.3.1 Within 14 days prior to starting the preparative regimen  
• Apheresis as indicated  
• Baseline blood test  
o Acute Care Panel (sodium, potassium, chloride, bicarbonate, creatinine, 
glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Creatinine Kinase, Lactate Dehydrogenase, Protein, total  
o Complete Blood Count with differential 
o PT/PTT 
o TBNK  
o Thyroid Panel 
o Urinalysis  
• Anti CMV antibody titer, HSV and VZV serology, and EBV panel. (may be performed within 3 months of chemotherapy) 
• Chest x -ray 
• EKG  
3.3.2 During the preparative regimen: DAILY 
• Complete Blood Count with differential 
• Acute Care Panel (sodium, potassium, chloride, bicarbonate, creatinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Creatinine Kinase, Lactate Dehydrogenase, Protein, total 
• Urinalysis  as needed  
• Daily weight as indicated  
• PT/PTT (every 3 days)  
3.3.3 After Cell Infusion: 
• Vital signs  will be monitored hourly (+/ - 15 minutes) for four hours  and then routinely 
(every 4 -6 hours) unless otherwise clinically indicated  
• Once total lymphocyte count is greater than 200/mm3, TBNK for peripheral blood CD4 count will be drawn weekly (while the patient is hospitalized) . Please refer to section 5 
for additional post cell infusion evaluations.  
3.3.4 During Hospitalization: 
• Every 1 -2 days 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 24 o A review of systems and physical exam  as clinically  indicated  
o CBC with differential  
o Acute Care Panel (sodium, potassium, chloride, bicarbonate, creatinine, glucose, 
BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Creatinine Kinase, Lactate Dehydrogenase, Protein, total  
o Troponin levels on days 4 and 7 and as clinically indicated 
o Other tests will be performed as clinically indicated.  
o Vital signs and weight will be monitored as clinically indicated. 
3.4 R
ETREATMENT  
Patients experiencing a partial or complete response may receive a second treatment when 
progression by RECIST criteria is documented after evaluation by the principal investigator.  
Patients will be retreated at the currently enrolling dose level  but will not count towards 
establishing the MTD. Patients who develop grade 3 or grade 4 toxicity due to cell infusion  will 
not be retreated. Patients must continue to meet the original eligibility criteria to be considered for retreatment.  Toxicity  related to cyclophosphamide, fludarabine , or aldeskeukin should be 
stable and resolved to less than grade 1 prior to retreatment.  Retreatment benefits and risks will 
be carefully explained to the patient.  A maximum of 1 retreatment course may occur.  
3.5 P
OST TREATM ENT EVALUATION  
• All patients will return to the NIH Clinical Center for their 1st evaluation for response 6 
weeks (+/ - 2 weeks) following the administration of the cell product 
• Patients who have received multiple transfusions during the treatment phase or discharged with grade 3 or greater significant adverse events should be evaluated by referring physician and repeat labs as appropriate within 2 weeks of discharge. Labs 
drawn should be faxed to the study coordinator. 
3.5.1 Time period of evaluations  
Patients wh o experience stable disease, a partial response, or a complete response or have 
unresolved toxicities will be evaluated as noted below:  
• Week 12 (+/- 2 weeks)  
• Every 3 months (+/- 1 month) x3 
• Every 6 months (+/- 1 month) x 2 years  
• As per PI discretion for s ubsequent years  
Note : Patients may be seen more frequently as clinically indicated  
3.5.2  
At each  scheduled evaluation , patients will undergo: 
• Physical examination , including weight and vital signs  
• Acute Care Panel (sodium, potassium, chloride, bicarbonate, creatinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, direct bilirubin), Mineral Panel (albumin, calcium, magnesium, phosphorus), Uric Acid, Creatinine Kinase, Lactate Dehydrogenase, Protein, total   
• Complete blood count with differential 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 25 • PT/PTT 
• Urinalysis as needed  
• Thyroid panel as clinically indicated  
• TBNK, until CD4 > 200 X 2  
• Toxicity assessment, including a review of systems.  
• Imaging (CT, MRI, and/or PET) as performed at baseline. 
• A 5liter apheresis may be performed . If a patient is unable to undergo apheresis, 
approximately 96 ml of blood may be obtained at the first follow up visit.  Subsequently, 
60 ml of blood will be obtained at follow up visits for at least 3 months. Peripheral blood 
mononuclear cells will be cr yopreserved so that immunologic testing may be performed. 
This will be performed on 03-C-0277.  
• Detection of RCR and persistence of gene transduced cells (See Section  5.1.5) 
• Long -term follow up of patients receiving gene transfer: Physical examinations will be 
performed and documented annually for 5 years following cell infusion to evaluate long-term safety.  After 5 years, health status data will be obtained from surviving patients via 
telephone contact or mailed questionnaires. The long term follow up period for retroviral vectors is 15 years. This will be performed on 09-C-0161. 
NOTE:  Patients who are unable or unwilling to return for follow up eval uations will be 
followed via phone or e -mail contacts.  A request will be made to send laboratory, imaging 
and physician exam reports performed b y their treating physician ; and any outstanding 
toxicities will be reviewed with the patient.  
3.6 C
RITERIA FOR REMO VAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to removal from study , effort must be made to have all subjects complete an evaluation 
safety visit approximately 6 weeks (± 2 weeks) following administration of the cell product (at the first follow -up evaluation).  
3.6.1 Criteria  for removal from protocol therapy 
Patients will be taken off treatment (and followed until progression of disease) for the following : 
• Completion of protocol therapy  
• Participant requests to withdraw from active therapy  
• Investigator discretion  
• Positive pregnancy test  
3.6.2 Off Study Criteria  
Patients will be taken off study for the following:  
• Completion of study follow up period 
• The participant requests to be withdrawn from study 
• Progressive disease , unless the patient is eligible for a second treatment 
• Lost to follow -up 
• Death  
Note: Once a subject is taken off study, no further data can be collected.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 26 Note:  Patients who are taken off study for progressive disea se or study closure maybe followed 
on Protocol 09 -C-0161 “Follow up Protocol for Subjects Previously Enrolled in Surgery Branch 
Studies”. Off Protocol Therapy and Off study procedure  
Authorized staff must notify Central Registration Office (CRO) when a subj ect is  taken off 
protocol therapy and when a subject is taken off -study. A Participant Status Updates Form  from 
the web site ( http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted email to:  NCI Central Registration Office 
ncicentralregistration -l@mail.nih.gov. 
4 CONCOMITANT MEDICATIONS/MEASURES  
4.1 INFECTION PROPHYLAXIS : 
Note: Other anti- infective agents may be substituted at the discretion of the treating physician .  
4.1.1  Pneumocystis Jirovecii Pneumonia  
All patients will receive the fixed combination of trimethoprim and sulfamethoxazole 
(TMP/SMX) as double strength (DS) tab (DS tabs = TMP 160 mg/tab, and SMX 800 mg/tab) P.O. daily three times a week on non -consecutive days, beginning day 0 or wi thin 1 week of 
lymphopenia.  
Dapsone (in G6PD sufficient patient), Atovaquone or Pentamidine may be substituted for 
TMP/SMX -DS in  patients with sulfa allergies.  
4.1.2 Herpes or Varicella Zoster Virus Prophylaxis  
Patients with positive HSV or VZV serology will be given valacyclovir orally at a dose of 500 
mg daily starting the day of cell infusion , or acyclovir, 250 mg/m
2 IV every  12 hrs if the patient 
is not able to take medication by mouth.  Reversible renal insufficiency has been reported with IV  
but not oral acyclovir.  Neurologic toxicity including delirium, tremors, coma, acute psychiatric 
disturbances, and abnormal EEGs has  been reported with higher doses of acyclovir. Should this 
occur, a dosage adjustment will be made or the drug will be discontinued. Acyclovir will not be 
used concomitantly with other nucleoside analogs which interfere with DNA synthesis, e.g. 
ganciclovir.  In renal disease, the dose is adjusted as per product labeling. 
Prophylaxis for Pneumocystis Varicella Zoster  and Herpes will continue for 6 months’ post 
chemotherapy.  If the CD4 count is less than 200 at 6 months’ post chemotherapy, prophylaxis 
will continue until the CD4 count is greater than 200 for 2 consecutive measures. 
4.1.3 Fungal Prophylaxis  
Patients will start Fluconazole 400 mg p.o. the day of cell infusion  and continue until the 
absolute neutrophil count is greater than 1000/mm3. The drug may be given IV at a dose of 400 
mg in 0.9% sodium chloride USP daily in patients unable to take it orally. 4.1.4 Empiric Antibiotics  
Patie nts will start on broad -spectrum antibiotics in accordance with current institutional 
guidelines for fever of 38.3°C once or two temperatures of 38.0°C or above at least one hour 
apart, AND an ANC <500/mm3. Infectious disease consultation will be obtained for all patients with unexplained fever or any infectious complications. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 27 4.2 BLOOD PRODUCT SUPPORT  
Using daily CBC’s as a guide, the patient will receive platelets and packed red blood cells 
(PRBC’s) as needed.  Attempts will be made to keep Hb >8.0 gm/dl, and plts > 10,000/mm3. All 
blood products will be irradiated. Leukocyte filters will be utilized for all blood and platelet transfusions to decrease sensitization to transfused WBC’s and decrease the risk of CMV infection. 
4.3 O
THER CONCOMITANT MEDICATIONS TO CONTR OL SIDE EFFECTS  
Concomitant medications to control side effects of therapy may be given.  Meperidine (25-50 mg) 
will be given intravenously if severe chilling develops.  Other supportive therapy will be given as 
required and may include acetaminophen (650 mg q4h), indomethacin (50- 75 mg q8h) and 
ranitidine (150 mg g12h). If patients require steroid therapy, they will be taken off treatment.  
Patients who require transfusions will receive irradiated blood products. Ondansetron 0.15 
mg/kg/dose IV every 8 hours will be administered for nausea and vomiting. Additional antiemetics will be administered as needed for nausea and vomitin g uncontrolled by 
ondansetron. Antibiotic coverage for central venous catheters may be provided at the discretion of the investigator.  
5 BIOSPECIMEN COLLECTI ON  
5.1 C
ORRELATIVE  STUDIES FOR RESEARCH :  
Blood and tissue are tracked at the patient level and can be linked to all protocols on which the patient has been enrolled. Samples will be used to support the specific objectives listed in the treatment protocol(s), e.g., immunologic monitoring, cytokine levels, persistence, as well as to 
support long term research efforts within the Surgery Branch and with collaborators as specified in our companion protocol, 03-C- 0277 (Cell Harvest and Preparati on for Surgery Branch 
Adoptive Cell Therapy Protocols).  
The amount of blood that may be drawn from adult patients for research purposes shall not exceed 10.5 mL/kg or 550 mL, whichever is smaller, over any eight- week  period . 
5.2 S
AMPLES SENT TO DR. FIGG’S LAB 
• Venous blood samples will be collected in either a 4ml or an 8ml SST tube to be processed for serum and stored for future research. Record the date and exact time of draw on the tube. Blood tubes may be kept in the refrigerator until pickup.  
• For sample pi ckup, page 102-11964. 
• For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 240-760-6190 (main clinical pharmacology lab number). 
• For questions regarding sample processing, contact Julie Barnes by e- mail or at 240 -760-
6044. 
• The samples will be processed, barcoded, and stored in Dr. Figg’s lab until requested by 
the investigator.  
5.3 S
AMPLES SENT TO SURGERY BRANCH CELL PROCESSING LABORATORY  
• Venous blood samples will be collected in 8ml CPT tubes to be processed and stored fo r 
future research. Record the date and exact time of draw on the tube. Blood tubes are kept 
at room temperature until pickup. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 28 • Samples will be pick -up by the research nurse or designee and transported to the SB Cell 
Processing Laboratory  within 24 hours of blood draw.  
• The samples will be processed, barcoded, and stored in SB Cell Processing Laboratory. 
5.3.1 Prior to chemotherapy administration : 
• 5 CPT tubes (8 ml each ) – SB’s lab  
• 1 SST tube (8 ml) – Figg’s lab  
• 1 SST tube (4ml) daily; starting the day chemotherapy begins – Figg’s lab 
5.3.2 Prior to c ell infusion (one 8ml SST) : 
• Baseline blood samples for cytokine analysis . – Figg’s lab  
5.3.3 Post cell infusion evaluations:  
Once total lymphocyte count is greater than 200/mm3, TBNK for peripheral blood CD4 count 
will be drawn and sent to the TIL lab on Monday, Wednesday and Friday x 5 days, then weekly 
(while the patient is hospitalized):  
• 5 CPT tubes (8 ml each)  – SB’s lab  
• 1 SST tube (8 ml) – Figg’s lab  
5.4 IMMUNOLOGICAL TESTING : 
• Apheresis may  be performed prior to and 4-6 weeks (+/- 2 weeks)  following the 
administration of the cell product . At other time points, patient peripheral blood 
lymphocytes (PBL) will be obtained from whole blood by purification using centrifugation on a Ficoll cushion. Aliquots of these PBMC will be  1) cr yopreserved 
for immunological monitoring of cell function  and 2) subjected to DNA and RNA 
extraction for PCR analysis of TCR and vector copy number estimation . 
• Lymphocytes will be tested directly and following in vitro culture. Direct immunological monitoring will consist of quantifying T cells reactive with MAGE -
A3/12 by FACS analysis using tetramer staining. Ex vivo immunological assays will 
consist of cytokine release by bulk PBL (+/- peptide stimulation) and by other experimental studies such as cytolysis i f sufficient cells are available. If cell numbers 
are limiting, preference will be given to the direct analysis of immunological activity.  Immunological assays will be standardized by the inclusion of 1) pre-
infusion PBMC and 2) an aliquot of the engineere d PBL cryopreserved at the time of 
infusion. In general, differences of 2 to 3 fold in these assays are indicative of true biologic differences. Foxp3 levels will be analyzed by semiquantitative RT -PCR to 
evaluate for mRNA on PBL samples obtained prior to cell infusion and at the follow up time point.  
5.5 M
ONITORING GENE THERAPY TRIALS : PERSISTENCE AND RCR:  
• Engineered cell survival. TCR and vector presence will be quantitated in PBMC samples usin g established PCR techniques. Immunological monitoring using both 
tetramer analysis and staining for the TCR will be used to augment PCR- based 
analysis.  This will provide data to estimate the in vivo survival of lymphocytes 
derived from the infused cells.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 29 • All patients will be co -enrolled on protocol 09 -C-0161 “ Follow up Protocol for 
Subjects Previously Enrolled in NCI Surgery Branch Studies ”. Patients blood 
samples will be obtained and undergo analysis for detection of RCR by PCR prior to 
cell infusion and RCR PCR will be performed at 3 and 6 months, and at one year post cell administration.  Blood samples will be archived annually thereafter if all 
previous testing has been negative with a brief clinical history. If a patient dies or develops neoplasms during this trial, efforts will be made to assay a biopsy sample for R CR. If any post -treatment samples are positive, further analysis of the RCR and 
more extensive patient follow -up will be undertaken, in consultation with the FDA. 
RCR PCR assays detect the GaLV envelope gene and are performed under contract by the Indiana University Vector Production Facility or other qualified testing 
facilities.  The results of these tests are maintained by the contractor performing the 
RCR tests and by the Surgery Branch research team. 
5.6 S
AMPLE STORAGE , TRACKING AND DISPOSITION  FOR SB CELL PROCESSING 
LABORATORY  
Blood and tissue collected during the course of this study will follow the Cell Tracking and Labeling System established by the Tumor Immunology Cell Processing Laboratory. The Cell Tracking and Labeling System is designed to unambigu ously ensure that patient/data verification 
is consistent.  The patients' cell samples (blood or tissue) are tracked by distinct identification 
labels that include a unique patient identifier and date of specimen collection.  Cryopreserved 
blood and tissue s amples also bear the date the sample was frozen.  All cryopreserved samples are 
tracked for freezer location and storage criteria.  All samples are stored in monitored 
freezers/refrigerators in 3NW Surgery Branch Laboratories at specified temperatures with alarm systems in place.  Serum samples will be sent to the Blood Processing Core  (BPC) for storage . 
Samples will be barcoded and stored on site or offsite at NCI Frederick Central Reposit ory 
Services in Frederick, MD. All samples  collected  (blood or tissue) are entered into a central 
computer database with identification and storage location, and this database is backed up every night. 
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the samples will be destroyed (or returned to the patient, if so requested), and reported as such to the IRB. Any samples lost (in transit or by a researcher) or destroyed due to unknown sample integrity (i.e. broken freezer allows for extensive sample thawing, etc.) will be reported as such to the IRB.  
Note:  Blood and tissue collected during the course of this study will be stored, tracked and 
disposed of as specified in our companion pr otocol 03 -C-0277, (Cell Harvest and Preparation for 
Surgery Branch Adoptive Cell Therapy Protocols).  
5.7 S
AMPLE STORAGE , TRACKING AND DISPOSITION FOR DR. FIGG’S LAB 
5.7.1 Sample Data Collection  
All samples sent to the Blood Processing Core (BPC) will be barcoded, with data entered and stored in the LABrador (aka LabSamples) utilized by the BPC, and data will be updated to the Surgery Branch central computer database weekly. This is a secure program, with access to LABrador limited to defined Figg lab personnel, who are issued individual user accounts. 
A b brevi ate d Title: A nti -M A G E -A 3 -D P 4 T C R P B L  
Versi o n D ate: J u ne 2 2, 2 0 1 8  
 3 0  I nstallati o n of L A Bra d or is li mite d t o c o m p uters s pecifie d b y Dr. Fi g g. T hese c o m p uters all ha ve 
a pass w or d restricte d l o gi n scree n. All Fi g g la b pers o n nel wit h access t o patie nt i nf or mati o n 
a n n uall y c o m plete t he NI H o nli ne Pr otecti o n of H u ma n S u bjects c o urs e.  
L A Bra d or creates a u ni q ue barc o de I D f or e ver y s a m ple a n d sa m ple b o x, w hic h ca n n ot be trace d 
bac k t o patie nts wit h o ut L A Bra d or access. T he data rec or de d f or eac h sa m ple i ncl u des t he 
patie nt I D, na me, trial na me/ pr ot oc ol n u m ber, ti me dra w n, c ycle ti me p oi nt, d os e, material t y pe, 
as well as b o x a n d freezer l ocati o n. Patie nt de m o gra p hics ass ociate d wit h t he cli nical ce nter 
patie nt n u m ber are pr o vi de d i n t he s yste m. F or eac h s a m ple, t here are n otes ass ociate d wit h t he 
pr ocessi n g met h o d ( dela y i n s a m ple pr ocessi n g, st ora ge c o n diti o ns o n t he war d, etc.). 
5. 7. 2  Sa m ple St ora ge a n d Destr ucti o n 
Barc o de d sa m ples are st ore d i n barc o de d b o xes i n a l oc ke d freezer at eit her - 2 0 or - 8 0 C 
acc or di n g t o sta bilit y re q uire me nts. T hese freezers  are l ocate d o nsite i n t he B P C a n d offsite at 
N CI Fre deric k Ce ntral Re p osit or y Ser vices i n Fre deric k, M D. Visit ors t o t he la b orat or y are 
re q uire d t o be acc o m pa ni e d b y la b orat or y staff at all ti mes.  
Access t o st ore d cli nical sa m ples is restricte d. Sa m ples will be st ore d u ntil re q ueste d b y a 
researc her na me d o n t he pr ot oc ol. All re q uests are m o nit ore d a n d trac ke d i n L A Bra d or. All 
researc hers are re q uire d t o si g n a f or m stati n g t hat t he sa m ples are o nl y t o b e us e d f or researc h 
p ur p os es ass ociate d wit h t his trial (as per t he I R B a p pr o ve d pr ot oc ol) a n d t hat a n y u n us e d 
sa m ples m ust be ret ur ne d t o t he B P C. It is t he res p o nsi bilit y of t he N CI Pri nci pal I n vesti gat or t o 
e ns ure t hat t he sa m ples re q ueste d are bei n g use d i n a ma n ner c o nsiste nt wit h I R B a p pr o val.  
F oll o wi n g c o m pleti o n of t his st u d y, s a m ples will re mai n i n st ora ge as detaile d a b o ve. A ccess t o 
t hese s a m ples will o nl y b e gra nte d f oll o wi n g I R B a p pr o val of a n a d diti o nal pr ot oc ol, gra nti n g 
t he ri g hts t o use t he material.  
If, at a n y ti me, a patie nt wit h dra ws fr o m t he st u d y a n d d oes n ot wis h f or t heir e xisti n g sa m ples t o 
be utilize d, t he i n di vi d ual m ust pr o vi de a writte n re q uest. F oll o wi n g recei pt of t his re q uest, t he 
sa m ples will be destr o ye d ( or ret ur ne d t o t he patie nt, if s o re q ueste d), a n d re p orte d as s uc h t o t he 
I R B. A n y s a m ples l ost (i n tra nsit or b y a res earc her) or destr o ye d d ue t o u n k n o w n s a m ple 
i nte grit y (i.e. br o ke n freezer all o ws f or e xte nsi ve sa m ple t ha wi n g, etc.) will be re p orte d as s uc h 
t o t he I R B.  
Sa m ple barc o des are li n ke d t o patie nt de m o gra p hics a n d li mite d cli nical i nf or mati o n. T his 
i nf or mati o n will o nl y be pr o vi de d t o i n vesti gat ors liste d o n t his pr ot oc ol, vi a re gistere d use of t he 
L A Bra d or. It is critical t hat t he s a m ple re mai ns li n ke d t o patie nt i nf or mati o n s uc h as race, a ge, 
dates of dia g n osis a n d deat h, a n d hist ol o gical i nf or mati o n a b o ut t he t u m or, i n or der t o c orrelate 
ge n ot y pe wit h t hes e varia bles. 
N ote:  Bl o o d a n d tiss ue c ollecte d d uri n g t he c o urse of t his st u d y will be st ore d, trac ke d a n d 
dis p ose d of as s pecifie d i n o ur c o m pa ni o n pr ot oc ol 0 3- C- 0 2 7 7, ( Cell H ar vest a n d Pre parati o n f or 
S ur ger y Bra nc h A d o pti ve Cell T hera p y Pr ot oc ols).   
6 D A T A C O L L E C TI O N A N D E V A L U A TI O N  
6. 1  DA T A CO L L E C TI O N  
T he PI will be res p o nsi ble f or o vers eei n g e ntr y of data i nt o a n i n -h o us e pass w or d pr otecte d 
electr o nic s yste m ( C 3 D) a n d e ns uri n g data acc urac y, c o nsiste nc y a n d ti meli ness. T he pri nci pal 
i n vesti gat or, ass ociate i n vesti gat ors/researc h n urses a n d/ or a c o ntracte d data ma na ger will assist 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 31 with the data management efforts.  All data obtained during the conduct of the pr otocol will be 
kept in secure network drives or in approved alternative sites that comply with NIH security 
standards. Primary and final analyzed data will have identifiers so that research data can be attributed to an individual human subject participant. Data will be entered into the NCI CCR C3D database.  
All adverse events ( AEs), including clinically significant abnormal findings on laboratory 
evaluations, regardless of severity, will be followed until return to baseline or stabilization of event. Patients will be followed for AEs until their first week 6 follow -up evaluation or until off-
study, whichever comes first. 
An abnormal laboratory value will be recorded in the database as an AE only if the laboratory 
abnormality is characterized by any of the following:  
• Results in discontinuation from the study 
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic i ntervention  
• Is associated with death or another serious adverse event, including hospitalization.  
• Is judged by the Investigator to be of significant clinical impact  
• If any abnormal laboratory result is considered clinically significant, the investigator w ill 
provide details about the action taken with respect to the test drug and about the patient’s 
outcome.  
All AEs must be recorded on the AE case report form unless otherwise noted below in Section  
6.1.1. 
End of study procedures: Data will be stored according to HHS and FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable .  
Loss or destruction of data: Should we become aware that a major bre ach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified.  
6.1.1 Exclusions to Routine Adverse Event Recording: 
Patients will be receiving multiple agents which include commercially available agents (fludarabine, cyclophosphamide and supportive medications) in combination with the investigational agents; therefore, grade 1 events not related to the cell product will not be reported/recorded.  
6.2 D
ATA SHARING PLAN 
6.2.1 Human Data Sharing Plan 
De-identified human data generated for use in future and ongoing research will be shared 
through a NIH-funded or approved repository (ClinicalTrials.gov) and BTRIS. At the completion of data analysis, data will be submitted to ClinicalTrials.gov either before publication or at the time o f publication or shortly thereafter.  Data may also be used to support long term research 
efforts within the Surgery Branch and de- identified data may also be shared with collaborators as 
specified in our companion protocol, 03-C- 0277 (Cell Harvest and Preparation for Surgery 
Branch Adoptive Cell Therapy Protocols).  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 32 6.2.2 Genomic Data Sharing Plan  
The NIH Genomic Data Sharing Policy does not apply to this study. 
6.3 RESPONSE  CRITERIA  
For the purposes of this study, patients should be re- evaluated for response at 6 and  12 weeks 
(+/- 2 weeks), then every 3 months (+/- 1 month) x3, then every 6 months’ (+/- 1 month) x 2 
years.  In addition to a baseline scan, confirmatory scans should also be obtained approximately 4 
(not less than 4) weeks following initial documentation of objective response. Clinical Response will be determined  using the Response Evaluation Criteria in Solid Tumors 
(RECIST) guideline (version 1.0).  6.3.1  Definitions  
Evaluable for toxicity: All patients will be evaluable for toxicity from the time of their first 
treatment with Cyclophosphamide.  
Evaluable for objective response: Only those patients who have measurable disease present at baseline, have received at least one cycle of therapy, and have had their disease re- evaluated will 
be considered evaluable fo r response.  These patients will have their response classified 
according to the definitions stated below. (Note:  Patients who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.) 
Evaluable Non -Target Disease  Response: Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of measurable disease, have received at least one cycle 
of therapy, and have had their disease re- evaluated will be considered evaluable for non -target 
disease. The response assessment is based on the presence, absence, or unequivocal progression 
of the lesions.  
6.3.2 Disease Parameters  
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in at 
least one dimension (lon gest diameter to be recorded) as :  
• By chest x -ray: >20 mm ;  
• By CT scan:  
o Scan slice thickness 5 mm or under as >10 mm with CT scan  
o Scan slice thickness >5 mm: double the slice thickness   
• With  calipers on clinical exam : >10 mm .  
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters).  
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, only the short axis will 
be measured and followed. 
Non-measurable dise ase: All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 33 effusions, lymphangitis cutis/pulmonitis, inflammatory breast dis ease, and abdominal masses 
(not followed by CT or MRI), are considered as non- measurable.  
Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected.  A 
sum of the diamet ers (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum. The baseli ne sum diameters 
will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease. 
Non-target lesions : All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up. 
6.3.3 Methods for Evaluation of Measurable Disease  
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow- up. Imaging- based evaluation is 
preferred to evaluatio n by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam.  
Clinical lesions: Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers 
(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is recommended.  
Conventional CT and MRI:  This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.   
MRI is also acceptable in certain situations (e.g. for body scans).  Ideally, the same type of 
scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath -hold scanning techniques , if 
possible. 
FDG -PET:  While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease). New lesion s on the basis of FDG-
PET imaging can be identified according to the following algorithm:  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 34 a) Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion. 
b) No FDG- PET at baseline and a positive FDG -PET at follow -up: If the positive FDG -PET 
at follow -up corresponds to a new site of disease confirmed by CT, this is PD. If the 
positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG -
PET scan).  If the positive FDG -PET at follow -up corresponds to a pre- existing site of 
disease on CT that is not progressing on the basis of the anatomic images, this is not PD. 
c) FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring.  The use of FDG -PET in this circumstance should be prospectively described in 
the protocol and supported by disease- specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and biopsy resolution/sens itivity.  
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image. 
6.3.4 Response Criteria  
6.3.4.1 Evaluation of target lesions
1  
• Complete Response (CR): Disappearance of all target lesions  
• Partial Response (PR):  At least a 30% decrease in the sum of the longest diameter 
(LD) of target lesions taking as reference the baseline sum LD.  
• Progression (PD):  At least a 20% increase in the sum of LD of target lesio ns 
taking as reference the smallest sum LD recorded since the treatment started or 
the appearance of one or more new lesions.  
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references  the smallest sum LD.  
6.3.4.2 Evaluation of non -target lesions
2  
• Complete Response (CR): Disappearance of all non -target lesions and 
normalization of tumor marker level.  
• Non-Complete Response: Persistence of one or more non -target lesions  
• Progression (PD):  Appeara nce of one or more new lesions. Unequivocal 
progression of existing non -target lesions  
-----------------------------------------------------------------------------------  
1 All measurable lesions up to a maximum of 10 lesions representative of all involved organs should be identified as target 
lesions  and recorded and measured at baseline.  Target lesions should be selected on the basis of their size (lesions with 
the longest diameter) and their suitability for accurate repetitive measurements (either by imaging techniques or clinically).  
A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD.  The 
baseline sum LD will be used as reference to further characterize the objective tumor response of the measurable 
dimension of the disease.  
2 All other lesions (or sites of disease) should be identified as non -target lesions and should also be recorded at baseline.  
Measurements are not required, and these lesions should be followed as “present” or “absent.”  
 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 35 6.3.4.3 Evaluation of best overall response  
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  The patient's best 
response assignment will depend on the achievement of both measurement and confirmation criteria.  
 
Target Lesions  Non-Target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/Non -PD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
6.3.5 Confirmatory Measurement/Duration of Response 
Confirmation  
To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat studies that should be performed at least 4 weeks after the criteria for response are first 
met. In the case of SD, follow- up measurements must have met the SD criteria at least once after 
study entry at a minimum interval of 6 -8 weeks. 
Duration of Overall Response  
The duration of overall response is measured from the time measurement criteria are met for CR/PR (whichever is first recorded) until the first date th at recurrent or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  
The duration of overall complete response is measured from the time measurement crit eria are 
first met for CR until the first date that recurrent disease is objectively documented.  
Duration of Stable Disease  
Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started.  
6.4 T
OXICITY CRITERIA  
The following adverse event management guidelines are intended to ensure the safety of each patient while on the study. The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40).  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 36 7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN  
7.1 DEFINITIONS  
7.1.1 Adverse Event  
Any untoward medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in research, whether or not considered related to the subject’s participation in the research  .  
7.1.2 Suspected adverse reaction  
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the drug caused the adverse ev ent. For the purposes of IND safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.  
7.1.3 Unexpected adverse reaction  
An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in 
the investigator brochure or is not listed at the specificity or severity that has been observed; or, 
if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application. "Unexpected”, also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
7.1.4 Serious  
An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious Adverse Event or if it compromises the safety, welfare or rights of subjects or others.  
7.1.5 Serious Adverse Event  
An adverse event or suspected adverse reaction is considered serious if in the view of the investigator or the sponsor, it results in any of the following: 
• Death  
• A life -threatening adverse drug experience  
• Inpatient hospitalization or prolongation of existing hospitalization  
• A persistent or significant disability/incapacity  or substantial disruption of the ability to 
conduct normal life functions.  
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
7.1.6 Disability  
A substantial disruption of a person’s ability to conduct normal life functions. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 37 7.1.7 Life-threatening adverse drug experience  
Any adverse event or suspected adverse reaction  that places the patient or subject, in the view of 
the investigator  or sponsor , at immediate risk of death from the reaction as it occurred, i.e., it 
does not include a reaction that had it occurred in a more severe form, might have caused death. 
7.1.8 Protocol Deviation (NIH Definition)  
Any change, divergence, or departure from the  IRB-approved research protocol.   
7.1.9 Non-compliance (NIH Definition)  
The failure to comply with applicable NIH Human Research Protections Program (HRPP) 
policies, IRB requirements, or regulatory requirements for the protection of human research subjects.  
7.1.10 Unanticipated  Problem 
Any incident , experience, or outcome that: 
•  Is unexpected in terms of nature, severity, or frequency in relation to  (a) the research risks that are described in the IRB -approved research protocol and informed 
consent document; Investigator’s Brochure or other study documents, and (b) the characteristics of the subject population being studied; AND  
• Is related or possibly related to participation in the research; AND  
• Suggest that the research places subjects or others at  a greater risk of harm  (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
7.2 NCI-IRB
 AND CLINICAL DIRECTOR (CD)  REPORTING  
7.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems  and Deaths  
The Protocol PI will report in the NIH Problem Form to the NCI- IRB and NCI Clinical 
Director : 
• All deaths, except deaths due to progressive disease 
• All Protocol Deviations  
• All Unanticipated Problems  
• All non- compliance  
Reports must be received within 7 days of PI awareness via iRIS.  
7.2.2 NCI-IRB Requirements for PI Reporting at Continuing Review 
The protocol PI will report to the NCI- IRB:  
1. A summary of all protocol deviations in a tabular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action. 
2. A summary of any instances of non -compliance  
3. A tabular summary of the following adverse events:  
• All Grade 2 unexpected  events that  are possibly, probably or definitely related to the 
research;  
• All Grade 3 and 4 events that are possibly, probably or definitely related to the 
research;  
• All Grade 5 events regardless of attribution;  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 38 • All Serious  Events regardless of attribution.  
NOTE : Grade 1 events are not required to be reported.  
7.2.3 NCI-IRB Report ing of IND Safety Reports 
Only IND Safety Reports that meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB. 
7.3 IND  SPONSOR REPORTING CRITERIA  
From the time the subject receives the investigational agent/intervention to the time of the first 
follow -up evaluation (6 weeks (± 2 weeks) following the administration of the cell product), the 
investigator must immediately report to the sponsor, using the mandatory MedWatch F orm FDA  
3500A or equivalent , any serious adverse even t, whether or not considered drug related, 
including those listed in the protocol or investigator brochure and must include an assessment of whether there is a reasonable possibility that the drug caused the event. For serious adverse events that occur  after the first follow -up evaluation, only those events that have an attribution of 
at least possibly related to the agent/intervention  will be reported . 
Required timing for reporting per the above guidelines: 
• Deaths (except death due to progressive disease)  must be reported via email within 24 
hours. A complete report must be submitted within one business day.  
• Other serious adverse events as well as deaths due to progressive disease must be 
reported within one business day 
Events will be submitted to the Center for Cancer Research (CCR) at: CCRsafety@mail.nih.gov  
and to the CCR PI and study coordinator. 
7.3.1 Waivier of expedited reporting to CCR  
The investigators are requesting a waiver from reporting specific events in an expedited manner 
to the CCR.  Patients will be receiving commercially available agents, such as fludarabine, 
cyclophosphamide, and aldesleukin. The majority of toxicities observed on Surgery Branch adoptive cell therapy protocols are expected toxicities of the non -myeloablative chemotherapy 
regimen or IL -2 and occur in approximately 95% of the patients enrolled, therefore, we are 
requesting a waive r from reporting the following events in an expedited manner to the CCR;  
• Grade 3 or greater myelosuppression, defined as lymphopenia, neutropenia, decreased hemoglobin, and thrombocytopenia. 
• Grade 3 or greater nausea, vomiting, mucositis - oral, anorexia, diarrhea, fever, chills, fatigue, and rash maculo -papular. 
• Grade 3 hypoxia, dyspnea, hematuria, hypotension, sinus tachycardia, urine output decreased, confusion, infections, and febrile neutropenia. 
The PI will submit a summary table of all grad e 3-5 events, whether or not considered related to 
the product, every 6 months. The report shall include the number of patients treated in the timeframe, the number of events per AE term per grade which occurred in the 6-month timeframe and in total since the start of the study, attribution, and type/category of serious. 
Reports will be submitted to the Center for Cancer Research (CCR) at: 
CCRsafety@mail.nih.gov . 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 39 7.3.2 Reporting Pregnancy  
7.3.2.1 Maternal exposure 
If a patient becomes pregnant during the first four months following treatment the pregnancy 
should be reported to the Sponsor. The potential risk of exposure of the fetus to the investigational agent(s) or chemotherapy agents (s) should be documented in box B5 of the Medwatch form “Describe Event or Problem”.  
Pregnancy itself is not regarded as a S AE unless there is a suspicion that the study treatment 
under study may have interfered with the effectiveness of a contraceptive medication. However, as patients who become pregnant on study risk intrauterine exposure of the fetus to agents which may be teratogenic, the CCR is requesting that pregnancy should be reported in an expedited manner as Grade 3 “Pregnancy, puerperium and perinatal conditions - Other (pregnancy)” under the Pregnancy, puerperium and perinatal conditions SOC.  
Congenital abnormalities or birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complications should not be handled as AEs. The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) should be followed up and documented. 
If any pregnancy occurs in the course of the study, then the investigator should inform the 
Sponsor within one day, i.e., immediately, but no later than 24 hours of when he or she becomes aware of it.  
The designated Sponsor representative will work with the investigator to ensure that all relevant information is provided to the Sponsor within 1 to 5 calendar days for SAEs and within 30 days for all other pregnancies.  
The same timelines apply when outcome information is available.  
7.3.2.2 Paternal exposure 
Male patients should refrain from fathering a child or donating sperm during the study and for 120 days after the last dose of aldesleukin. Pregnancy of the patient’s partner is not considered to be an AE. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) occurring from the date of the first dose until 120 days after the last dose should, if possible, be followed up and documented. 
7.4 I
NSTITUTIONAL BIOSAFETY COMMITTEE (IBC)  REPORTING CRITERIA  
7.4.1 Serious Adverse Event  Reports to IBC  
The Principal Investigator  (or delegate) will notify  IBC  of any unexpected fatal or life -
threatening experience associated with the use of  Anti- MAGE -A3-DP4 TCR PBL  as soon as 
possible but in no event later than 7 calendar days of initial receipt of the information.  Serious 
adverse events  that are unexpected and associa ted with the use of the Anti- MAGE -A3-DP4 TCR 
PBL, but are not fatal or life -threatening, must be reported to the NIH IBC as soon as possible, 
but not later than 15 calendar days after the investigator’s initial receipt of the information.  
Adverse events ma y be reported by using the FDA Form 3500a. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 40 7.4.2 Annual Reports to IBC 
Within 60 days after the one- year anniversary of the date on which the IBC approved the initial 
protocol , and after each subsequent anniversary until the trial is completed, the Principal 
Investigator (or delegate) shall submit the information described below.  Alternatively, the IRB 
continuing review report can be sent to the IBC in lieu of a separate report.  Please include the 
IBC protocol number on the report. 
7.4.2.1 Clinical Trial Information   
A brief summary of the status of the  trial in progress or completed during the previous year. The 
summary is required to include the following information for each trial:  
• the title and purpose of the trial  
• clinical site  
• the Principal Investigator  
• clinical protocol identifiers  
• participant population (such as disease indication and general age group, e.g., adult or 
pediatric);  
• the total number of participants planned for inclusion in the trial; the number entered into the trial to date  whose participation in  the trial was completed; and the number who 
dropped out of the trial with a brief description of the reasons   
• the status of the trial, e.g., open to accrual of subjects, closed but data collection ongoing, 
or fully completed,  
• if the trial has been comple ted, a brief description of any study results.  
7.4.2.2 Progress Report and Data Analysis   
Information obtained during the previous year's clinical and non- clinical investigations, 
including: 
• a narrative or tabular summary showing the most frequent and most serious adverse 
experiences by body system  
• a summary of all serious adverse events submitted during the past year 
• a summary of serious adverse events that were expected or considered to have causes not associated with the use of the gene transfer product such as  disease progression or 
concurrent medications  
• if any deaths have occurred, the number of participants who died during participation in the investigation and causes of death  
• a brief description of any information obtained that is pertinent to an understanding of the gene transfer product’s actions, including, for example, information about dose-response, information from  controlled trials, and information about bioavailability.  
7.5 D
ATA AND SAFETY MONITORING PLAN 
7.5.1 Principal  Investi gator/Research Team   
The clinical research team will meet on a regular basis when patients are being actively treated on the trial to discuss each patient. Decisions about dose level enrollment and dose escalation if applicable will be made based on the toxicity data from prior patient s.  
All data will be collected in a timely manner and reviewed by the principal investigator or a lead associate investigator. Adverse events will be reported as required above. Any safety concerns, 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 41 new information that might affect either the ethical and or scientific conduct of the trial, or 
protocol deviations will be immediately reported to the IRB using iRIS .  
The principal investigator will review adverse event and response data on each patient to ensure safety and data accuracy. Th e principal investigator will personally conduct or supervise the 
investigation and provide appropriate delegation of responsibilities to other members of the research staff.  
7.5.2 Sponsor Monitoring Plan 
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring program. The CCR’s program allows for confirmation of: study data, specifically data that could affect the interpretation of primary study endpoints; adherence to the protocol, regulations, and SOPs; and human subject’s protection. This is done through independent verification of study data with source documentation focusing on: 
• Informed consent process 
• Eligibility confirmation  
• Drug administration and accountability 
• Adverse events monitoring  
• Response assessment.  
The monitor ing program also extends to multi-site research when the CCR is the coordinating 
center.  
This trial will be monitored by personnel employed by a CCR contractor. Monitors are qualified by training and experience to monitor the progress of clinical trials. Personnel monitoring this study will not be affiliated in any way with the trial conduct.  
7.5.3 Safety Monitoring Committee (SMC)  
This protocol will require oversight from the Safety Monitoring Committee (SMC). Initial review will occur as soon  as possible after the annual NCI -IRB continuing review date. 
Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting schedule permits or more frequently as may be required by the SMC. For initial and subsequent reviews, protocols will not be reviewed if there is no accrual within the review period. Written outcome letters will be generated in response to the monitoring activities and submitted to the Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.  
8 STATISTICAL CONSIDERATIONS   
Following an initial portion of the study in which the safety of cells used in this protocol will be determined, the primary objective of this trial is to determine whether the combination of high dose aldesleukin, lymphocyte-depleting chemotherapy, and an infusion of anti- MAGE -A3-DP4-
TCR -gene engineered  lymphocytes is able to be associated with a modest fraction of patients that 
can experience a clinical  response (PR +CR) to therapy. A secondary objective is to have 
sufficient p atients in order to do exploratory evaluations of survival of cells.  
The study will begin by evaluating the safety of escalating doses of cells from 10
7 to 1011. Once 
a safe dose has been confirmed, patients will be enrolled into the phase 2 portion of the trial 
using the cell dose found to be safe in the first phase of this protocol. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 42 Following the determination of a safe cell dose, the following will describe the phase 2 portion 
of the study.  
Patients who express MAGE -A3-DP4 will be enrolled into individual strata depending on their 
specific histology.  This stratification is being used to separate patients who have been shown 
historically to be aldesleukin sensitive (melanoma) fro m those who have not.  In each case, the 
MAGE -A3-DP4 expression is expected to be so dominant in regulating potential for response 
that differences in clinical response according to histology will not be expected but will be evaluated in an exploratory mann er to help assess this, in a pilot sense.  
For each of the 2 strata, the study will be conducted using a phase 2 optimal design (Simon R, Controlled Clinical Trials 10:1 -10, 1989). For both strata, the objective will be to determine if 
the combination of high dose aldesleukin, lymphocyte depleting chemotherapy, and anti- MAGE -
A3-DP4-TCR -gene engineered lymphocytes is able to be associated with a clinical response rate 
that can rule out 5% (p0=0.05) in favor of a modest 20% PR + CR rate (p1=0.20). 
In patien ts in each of the two strata (melanoma vs. other histologies  or renal carcinoma), the 
following design will be used. For each strata, with alpha=0.05 (5% probability of accepting a 
poor therapy) and beta=0.10 (10% probability of rejecting a good therapy,), initially 21 evaluable patients will be enrolled.  If 0 or 1 of the 21 patients experiences a clinical response, then no 
further patients will be enrolled.  If 2 or more of the first 21 evaluable patients enrolled have a 
clinical response, then accrual will continue until a total of 41 evaluable patients have been enrolled. As it may take several weeks to determine if a patient has experienced a clinical response, a temporary pause of up to 6 months in the accrual to the trial may be necessary to ensure that  enrollment to the second stage is warranted.  If 2 to 4 of the 41 have a clinical 
response, then this will be considered inadequate for further investigation. If 5 or more of 41 patients have a clinical response, then this will indicate that this strategy provides a new approach that may be worthy of further consideration. Under the null hypothesis (5% response rate), the probability of early termination is 72%.  
Further, to help ensure that maldistribution of patients who are either particularly responsive or unresponsive in the first stage does not materially interfere with the intended use of the two -stage 
design, we will aim to enroll 4 -5 patients of each allowed histology among the first 21 enrolled 
in the ‘other histology’ arm.  Although this has its own inherent issues due to limited sample size, 
since we believe that these ‘other histologies’ will behave the same clinically, it will permit us to evaluate the different response rates in a limited number of subjects and determine if they differ markedly o r not.  Since this would merely be an exploratory analysis, we will also look at minor 
response as well to help evaluate for hints of efficacy.  If the response rates do seem to potentially 
differ markedly by histology, despite our hypothesis that this will not happen, we may consider amending the protocol when appropriate to try to restrict enrollment to those histologies with stronger evidence of responsiveness.  For patients with breast cancer or other chemotherapy -
sensitive tumors (i.e. sarcoma), only responses seen at day 28 and maintained at 4 months will be considered a positive response for accrual to the second phase of this study. 
The dose escalation portion of the study may require 6 patients per cohort . For purposes of 
sample size estimation, we will assume that as few as 9 and no more than 25 patients will be 
required to perform the initial safety evaluation. In order to complete the dose escalation phase 
and both phase 2 cohorts, a total of up to 25+82= 107 patients may be required (25 + 2 strata with 
a maximum of 41 apiece).  Up to 6 patients enrolled at the MTD will count towards the accrual in 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 43 the appropriate phase 2 strata if they are evaluable for response and if they would be fully 
eligible for enrollment in the phase 2 portion of the trial. Provided that about 4-5 patients per month will be able to be enrolled onto this trial, approximately 2 years may be needed to accrual the maximum number of required patients. However, as adequate responses to proceed to the second stage of accrual may n ot occur, the trial may end up accruing as few as 9 +42=57 patients 
if no arm demonstrates sufficient patients to accrue a second stage.  
9 COLLABORATIVE AGREEMENTS  
We have established a Cooperative Research and Development Agreement (CRADA s #02716 
and #03168) with Kite Pharma, Inc., and will be sharing data with them. 
10 HUMAN SUBJECTS PROTECTIONS  
10.1 R
ATIONALE FOR SUBJECT SELECTION  
The patients to be entered in this protocol have metastatic cancer which is refractory to standard 
therapy, and limited life expectan cies. 
Subjects from both genders and all racial/ethnic groups are eligible for this study if they meet the 
eligibility criteria. To date, there is no information that suggests that differences in drug 
metabolism or disease response would be expected in one group compared to another. Efforts 
will be made to extend accrual to a representative population, but in this preliminary study, a balance must be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic and/or ineffective treatments on the one hand and the need to explore gender and ethnic aspects of clinical research on the other hand. If differences in outcome that correlate to gender or to ethnic identity are noted, accrual may be expanded o r a 
follow -up study may be written to investigate those differences more fully.  
10.2 P
ARTICIPATION OF CHILDREN  
The use of the nonmyeloablative regimen in this protocol is a major procedure which entails serious discomforts and hazards for the patient, such that fatal complications are possible.  It is 
therefore only appropriate to carry out this experimental procedure in the context of life threatening metastatic cancer. Since the efficacy of this experimental procedure is unknown, it does not seem reasonable to expose children to this risk without further evidence of benefit. Should results of this study indicate efficacy in treating metastatic cancer, which is not responsive to other standard forms of therapy, future research can be conducted in the pediatric population to evaluate potential benefit in that patient population.  
10.3 P
ARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT  
Adults unable to give consent are excluded from enrolling in the protocol. However re -consent 
may be necessary and there is a possibility, though unlikely, that subjects could become decisionally impaired. For this reason and because there is a prospect of direct benefit from research participation (section 10.5), all subjects ≥ age 18 will be offered the opportunity to fill in their wishes for research and care, and assign a substitute decision maker on the “NIH Advance Directive for Health Care and Medical Research Participation” form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team for evaluation . For those subjects that become 
incapacitated and do not have pre-determined substitute decision maker, the procedures 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 44 described in MAS Policy 87 -4 for appointing a surrogate decision maker for adult subjects who 
are (a) decisionally impaired, and (b)  who do not have a legal guardian or durable power of 
attorney, will be followed.  
10.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
The experimental treatment has a chance to provide clinical benefit though it is not known if it 
will do so. The risks in this tr eatment are detailed in section 11. The success of this effort cannot 
be predicted at this time.  
10.5 RISK/BENEFIT ANALYSIS  
Because all patients in this protocol have metastatic cancer , which is refractory to standard 
therapy  and limited life expectancies , the potential benefit is thought to outweigh the potential 
risks.  
10.6 CONSENT PROCESS AND DOCUMENTATION  
If the patient has a tu mor that is found to be HLA- DP4 positive and MAGE -A3 positive by 
immunohistochemistry, the patient is consented on protocol 03-C-0277, Cell Harvest and 
Preparation for Surgery Branch Adoptive Cell Therapy Protocols.  If the lymphocytes  can be 
generated for infusion and the patient meets the thorough screening for eligibility, the patient, 
with family members or friends at the request of the patient, will be presented with a detailed 
description of the protocol treatment.  The specific requirements, objectives , and potential 
advantages and disadvantages will be presented. The Informed Consent document is given to the patient, who is requested to review it and to ask questions prior to agreeing to participate in the treatment portion of this protocol.  The patien t is reassured that participation on trial is entirely 
voluntary and that he/she can withdraw or decide against treatment at any time without adverse consequences. The P rincipal I nvestigator, associate investigator, or clinical fellow is responsible 
for obtaining written consent from the patient. 
10.6.1 Informed consent of non- English speaking subjects:  
If there is an unexpected enrollment of a research participant for whom there is no translated 
extant IRB approved consent document, the principal investigator and/or those authorized to obtain informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77 -2, OHSRP SOP 12, 45 CFR 46.117 (b) (2), and 21 CFR 50.27 (b) (2). The summary 
that will be used is the English version of the extant IRB approved consent document. Signed copies of both the English version of the consent and the translated short form will be given to the subject or their legally authorized representative and the signed original will be filed in the medical record.  
Unless the PI is fluent in the prospective subject’s language, an interpreter will be present to facilitate the conversation (using either the long translated form or the short form). Preferably someone who is independent of the subject (i.e., not a family member) will assist in presenting information and obtaining consent. Whenever possible, interpreters will be provided copies of the relevant consent documents well before the consent conversation with the subject (24 to 48 hours if possible).  
We request prospective IRB approval of the use of the short form process for non -English 
speaking subjects and will notify the IRB at the time of continuing review of the frequency of the use of the Short Form.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 45 11 PHARMACEUTICAL  INFORMATION  
11.1 INVESTIGATIONAL INVESTIGATION  
11.1.1 Cell Preparation (ANTI -MAGE -A3-DP4 TRANSDUCED PBL)  
The procedure for expanding the human PBL and the certificate of analysis are similar to those 
approved by the food and drug administration and used at the NCI in ongoing pro tocols 
evaluating cell therapy in the surgery branch.  The certificate of analy sis is included in Appendix 
5. The PBL will be transduced with retroviral supernatant containing the alpha chain and beta chain genes of the Anti- MAGE -A3-DP4.  
Note:  Penicillin, Streptomycin, and gentamycin will not be used in the manufacture of products 
for patients with documented allergies to these drugs.  
11.1.1.1 Retroviral Vector Containing the Anti-Mage- A3-DP4 Gene  
The retroviral vector supernatant [PG13 -MAGE -A3 TCR encoding a T cel l receptor directed 
against MAGE -A3-DP4, was prepared and preserved following cGMP conditions in the Surgery 
Branch Vector Production Facility (SBVPF). The retroviral vector, PG13 -MAGE -A3 6F9mC 
TCR (B8), consists of 7,382 bps including the 5' LTR from the murine stem cell virus 
(promoter), packaging signal including the splicing donor (SD) and splicing acceptor sites, alpha 
chain and beta chain genes of the anti -MAGE -A3-DP4 TCR. The alpha and beta chains are 
linked by a P2A peptide. For clone selection, the physical titer will be determined by RNA dot blot. The physical titer of the clinical vector will be measured in transducing units per mL 
following a titration on human PBL according to sponsor protocols.  The supernatant has been 
stored at the SBVPF upon the completion of production at –80 °C. A portion of the supernatant will be shipped on dry ice and stored –80 °C at Fisher Bioservices, Rockville, MD. This storage facility is equipped with around-the-clock temperature monitoring. Upon request, supernatan t 
will be delivered on dry ice to be used in in vitro transduction. There will be no re- use of the 
same unit of supernatant for different patients. Retroviral titer has been shown to be stable after immediate thawing and immediate administration (coating the tissue culture wells previously coated with Retronectin). Handling of the vector should follow the guidelines of Biosafety Level -2 (BSL -2). The specific guidelines for Biosafety Level -2 (BSL -2) can be viewed at 
http://bmbl.od.nih.gov/sect3bsl2.htm.  
11.1.2 Interleukin-2 (Aldesleukin, Proleukin, Recombinant Human Interleukin 2) 
How Supplied: Interleukin-2 (aldesleukin) will be provided by the NIH Clinical Pharmacy 
Department from commercial sources.   
Formulation/Reconstitution : Aldesleukin, NSC #373364, is provi ded as single -use vials 
containing 22 million IU ( −1.3 mg) IL -2 as a sterile, white to off -white lyophilized cake plus 50 
mg mannitol and 0.18 mg sodium dodecyl sulfate, buffered with approximately 0.17 mg 
monobasic and 0.89 mg dibasic sodium phosphate to a pH of 7.5 (range 7.2 to 7.8). The vial is reconstituted with 1.2 mL of Sterile Water for Injection, USP, and the resultant concentration is 18 million IU/m L or 1.1 mg/mL. Diluent should be directed against the side of the vial to avoid 
excess foaming. Swirl contents gently until completely dissolved. Do not shake. Since vials 
contain no preservative, reconstituted solution should be used with 24 hours. 
Storage: Intact vials are stored in the refrigerator (2 ° - 8°C) protected from light. Each vial bears 
an expiration date.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 46 Dilution/Stability : Reconstituted aldesleukin should be further diluted with 50 mL of 5% Human 
Serum Albumin (HSA). The HSA should be added to the diluent prior to the addition of RIL-2. 
Dilutions of the reconstituted solution over a 1000-fold range (i.e., 1 mg/mL to 1 mcg/mL) are 
acceptable in either glass bottles or polyvinyl chloride bags.  Aldesleukin is chemically stable for 
48 hours at refrigerated and room temperatures, 2° – 30°C.  
Administration: The dosage will be calculated based o n total body weight.  The final dilution of 
aldesleukin will be infused over 15 minutes. Aldesleukin will be administered as an inpatient.   
Toxicities: Expected toxicities of aldesleukin are listed in the product label and in Appendix 2  
and Appendix 3. Grade 3 toxicities common to aldesleukin include diarrhea, nausea, vomiting, 
hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and laboratory changes as detailed in Appendix 2. Additional grade 3 and 4 toxicities seen with 
aldesleukin are detailed in Appendix 3. 
11.1.3 Fludarabine 
(Please refer to package insert for complete product i nformation)  
Description : Fludarabine phosphate is a synthetic purine nucleoside that differs from physiologic 
nucleosides in that the sugar moiety is arabinose instead of ribose or deoxyribose. Fludarabine is 
a purine antagonist antimetabolite.  
How Supplied:  It will be purchased by the NIH Clinical Pharmacy Department from commercial 
sources. Fludarabine is supplied in a 50 mg vial as a fludarabine phosphate powder in the form of a white, lyophilized solid cake.  
Stability:  Following reconstitution with 2 mL of sterile water for injection to a concentration of 
25 mg/m L, the solution has a pH of 7.7. The fludarabine powder is stable for at least 18 months 
at 2-8°C; when reconstituted, fludarabine is stable for at least 16 days at room temperature. 
Because no preservative is present, reconstituted fludarabine will typically be administered within 8 hours. Specialized references should be consulted for spec ific compatibility 
information.  Fludarabine is dephosphorylated in serum, transported intracellularly and converted 
to the nucleotide fludarabine triphosphate; this 2 -fluoro -ara-ATP molecule is thought to be 
required for the drug’s cytotoxic effects. Fludarabine inhibits DNA polymerase, ribnucleotide reductase, DNA primase, and may interfere with chain elongation, and RNA and protein synthesis. 
Storage:  Intact vials should be stored refrigerated (2 -8°C). 
Administration : Fludarabine is administered as an IV infusion in 100 mL 0.9% sodium c hlori de, 
USP over 15 to 30 minutes. The doses will be based on body surface area (BSA). If patient is obese (BMI > 35) drug dosage will be calculated using practical weight as described in 
Appendix 1. 
Toxicities:  At doses of 25 mg/m2/day for 5 days, the primary side effect is myelosuppression; 
however, thrombocytopenia is responsible for most cases of severe and life-threatening hematologic toxicity.  Serious opportunistic infections have occurred in CLL patients treated with 
fludarabine.  Hemolytic anemia has been reported after one or more courses of fludarabine with 
or without a prior history of a positive Coomb’s test; fatal hemolytic anemia has been  reported.  
In addition, bone marrow fibrosis has been observed after fludarabine therapy. Other common adverse effects include malaise, fever, chills, fatigue, anorexia, nausea and vomiting, and 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 47 weakness. Irreversible and potentially fatal central nervous system toxicity in the form of 
progressive encephalopathy, blindness, and coma is only rarely observed at the currently administered doses of fludarabine. More common neurologic side effects at the current doses of fludarabine include weakness, pain, malaise, fatigue, paresthesia, visual or hearing disturbances, and sleep disorders. Adverse respiratory effects of fludarabine include cough, dyspnea, allergic 
or idiopathic interstitial pneumonitis.  Tumor lysis syndrome has been rarely observed in 
fludarabine treatment of CLL.  Treatment on previous adoptive cell therapy protocols in the 
Surgery Branch have caused persistently low (below 200) CD4 counts, and one patient developed polyneuropathy manifested by vision blindness, and motor and sensory defects. 
11.1.4 Cyclo phosphamide 
(Refer to FDA -approved package insert for complete product  information): 
Description:  Cyclophosphamide is a nitrogen mustard- derivative alkylating agent.  Following 
conversion to active metabolites in the liver, cyclophosphamide functions as an alkyating agent; 
the drug also possesses potent immunosuppressive activity. The serum half- life after IV 
administration ranges from 3-12 hours; the drug and/or its metabolites can be detected in the serum for up to 72 hours after administration.  
How Suppl ied: Cyclophosphamide will be obtained from commercially available sources by the 
NIH Clinical Center Pharmacy Department.  
Stability:  Following reconstitution as directed with sterile water for injection, cyclophosphamide 
is stable for 24 hours at room temperature or 6 days when kept at 2-8°C.  
Administration:  It will be diluted in 250 mL D5W and infused over one hour.  The dose will be 
based  on the patient’s body weight. If patient is obese (BMI > 35) drug dosage will be calculated 
using practical weight as described in Appendix 1 . 
Toxicities:  Hematologic toxicity occurring with cyclophosphamide usually includes leukopenia 
and thrombocytopenia. Anorexia, nausea and vomiting, rash and alopecia occur, especially after high-dose cyclophosphamide; diarrhea, hemorrhagic colitis, infertility, and mucosal and oral ulceration have been reported.  Sterile hemorrhagic cystitis occurs in about 20% of patients; 
severity can range from microscopic hematuria to extensive cystitis with  bladder fibrosis. 
Although the incidence of hemorrhagic cystitis associated with cyclophosphamide appears to be lower than that associated with ifosfamide, mesna (sodium 2 -mercaptoethanesulfonate) has been 
used prophylactically as a uroprotective agent in  patients receiving cyclophosphamide. 
Prophylactic mesna is not effective in preventing hemorrhagic cystitis in all patients.  Patients 
who receive high dose cyclophosphamide may develop interstitial pulmonary fibrosis, which can be fatal.  Hyperuricemia due to rapid cellular destruction may occur, particularly in patients with 
hematologic malignancy.  Hyperuricemia may be minimized by adequate hydration, 
alkalinization of the urine, and/or administration of allopurinol.  If allopurinol is administered, 
patients should be watched closely for cyclophosphamide toxicity (due to allopurinol induction of hepatic microsomal enzymes).  At high doses, cyclophosphamide can result in a syndrome of 
inappropriate antidiuretic hormone secretion; hyponatremia with progressive weight gain without 
edema occurs.  At high doses, cyclophosphamide can result in cardiotoxicity. Deaths have 
occurred from diffuse hemorrhagic myocardial necrosis and from a syndrome of acute myopericarditis; in such cases, congestive heart failure may occu r within a few days of the first 
dose.  Other consequences of cyclophosphamide cardiotoxicity include arrhythmias, potentially 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 48 irreversible cardiomyopathy, and pericarditis. Other reported adverse effects of 
cyclophosphamide include headache, dizziness, and myxedema; faintness, facial flushing, and 
diaphoresis have occurred following IV administration. Mesna (sodium 2-
mercaptoethanesulphonate; given by IV injection) is a synthetic sulfhydryl compound that can chemically interact with urotoxic metabolites of cyclophosphamide (acrolein and 4-hydroxycyclophosphamide) to decrease the incidence and severity of hemorrhagic cystitis.  
11.2 S
UPPORTIVE MEDICATIONS  
11.2.1 Mesna  
(Sodium 2 -mercaptoethanesulfonate, Mesnum, Mesnex, NSC -113891)  
(Please refer to the FDA -approved package insert for complete product information)  
Description:  Mesna will be obtained commercially by the Clinical Center Pharmacy Department 
and is supplied as a 100 mg/m L solution.   
Storage:  Intact ampoules are stored at room temperature.   
Stability:  Diluted solutions (1 to 20 mg/mL) are physically and chemically stable for at least 24 
hours under refrigeration. Mesna is chemically stable at room temperature for 48 -72 hours in 
D5W, 48-72 hour in D5W/0.45% NaCl, or 24 hours in 0.9% NaCl. 
Administration:  Dilute to concentrations less than or equal to 20 mg mesna/mL fluid in D5W or 
0.9% NaCl and to be administered intravenously as a continuous infusion. If patient is obese 
(BMI > 35) drug dosage will be calculated using practical weight as described in Appendix 1. 
Toxicities include  nausea, vomiting and diarrhea. 
11.2.2 Filgrastim  
(Granulocyte Colony-Stimulating Factor, G- CSF, Filgrastim, Neupogen)  
Filgrastim will be obtained commercially by the Clinical Center Pharmacy Department and is 
supplied in 300 ug/mL and 480 ug/1.6 mL vials.  G-CSF should be refrigerated and not allowed 
to freeze.  The product bears the expiration date. The product should not be shaken. It is generally 
stable for at least 10 months when refrigerated.  The appropriate dose is drawn up into a syringe. 
G-CSF will be given as a daily subcutaneous injection. The side effects of G -CSF are skin rash, 
myalgia and bone pain, an increase of preexisting inflammatory conditions, enlarged spleen with occasional associated low platelet counts, alopecia (with prolonged use) elevated blood chemistry levels.  
11.2.3 Trimethoprim and Sulfamethoxazole Double Strength (TMP / SMX DS): 
TMP/SMX DS will be obtained by the  Clinical Center Pharmacy Department from commercial 
sources.  It will be used for the prevention of PCP pneumonia. The oral dose is 1 tablet PO daily 
three times a week (MUST be on non -consecutive days) beginning on day 0 or within one week 
of anticipated lymphopenia and continuing for at least 6 months and until the CD4 count is greater than 200 on 2 consecutive lab studies. Like other sulfa drugs, TMP/SMX DS can cause allergies, fever, photosensitivity, nausea, and vomiting. Allergies typically develop as a 
widespread itchy red rash with fever eight to fourteen days after beginning the standard dose. Neutropenia, a reduction in the number of neutrophils, can also occur. Should allergies develop, the following medications may be used in place of TMP/SMX DS. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 49 11.2.3.1 Dapsone  
Dapsone will be obtained by the Clinical Center Pharmacy Department from commercial 
sources. It will be used for the prevention of Pneumocystis pneumonia. The dose is 100mg by mouth daily, starting on day 0 (± 7 days) and continuing at least 6 months and until the CD4+ count is > 200 on two consecutive lab studies. It is supplied as 25mg and 100mg tablets. Dapsone contains a sulfa group, although the cross reactivity in patients with sulfa allergies is quite low. Dapsone may be considered in patie nts with mild to moderate sulfa allergies. Dapsone 
should be avoided in patients with severe (i.e., a history of anaphylaxis or other equally serious reaction) reactions to sulfa drugs. Additionally, dapsone has been reported to cause hemolytic anemia is patients with G6PD deficiency. It is recommended that patients be tested for G6PD deficiency prior to the initiation of dapsone therapy. Dapsone is generally well tolerated, but may cause a number of hematologic adverse reactions, including increased reticu locyte counts, 
hemolysis, decreased hemoglobin, methemoglobinemia, agranulocytosis, anemia, and leukopenia. Other rare but serious adverse reactions include bullous exfoliative dermatitis, Stevens -Johnson syndrome, toxic epidermal necrolysis, pancreatitis, interstitial pneumonitis, and 
pulmonary eosinophilia. For more detailed information about adverse reactions, consult the package insert.  
11.2.3.2 Atovaquone  
Atovaquone will be obtained by the Clinical Center Pharmacy Department from commercial sources. It will be  used for the prevention of Pneumocystis pneumonia in patients who cannot 
tolerate or are allergic to sulfamethoxazole/trimethoprim, dapsone, or pentamidine. Atovaquone may be given as a single daily dose of 1500mg orally or the dose may be split into 750mg given orally twice daily. Atovaquone will be started on day 0 (± 7 days), and will continue for at least 6 months and until the CD4+ count is > 200 on two consecutive lab studies. Atovaquone is supplied as an oral suspension containing 150mg/mL. Common a dverse reactions to atovaquone 
include: headache, rash, diarrhea, nausea, vomiting, abdominal pain, cough, and fever. Rare but serious adverse reactions include acute renal failure, hepatitis and hepatic failure, angioedema, pancreatitis, and Stevens -Johnson syndrome. For more detailed information about adverse 
reactions, consult the package insert.  
11.2.3.3 Aerosolized Pentamidine  
Patients with sulfa allergies will receive aerosolized Pentamidine 300 mg per nebulizer with one week prior to admission and continued monthly until the CD4 count is above 200 on two consecutive follow up lab studies and for at least 6 months post chemotherapy. Pentamidine Isethionate will be obtained by the Clinical Center Pharmacy Department from commercial sources.  It will be used to p revent the occurrence of PCP infections.  It is supplied in 300 mg vials 
of lyophilized powder and will be administered via nebulizer. Toxicities reported with the use of Pentamidine include metallic taste, coughing, bronchospasm in heavy smokers and asthma tics; 
increased incidence of spontaneous pneumothorax in patients with previous PCP infection or pneumatoceles, or hypoglycemia.  
11.2.4 Herpes and Varicella Zoster Virus Prophylaxis  
11.2.4.1 Valacyclovir (Valtrex)  
Valacyclovir will be obtained by the Clinical Center Ph armacy Department from commercial 
sources.  It will be used orally to prevent the occurrence of herpes virus infections in patients with 
positive HSV serology.  It is supplied in 500 mg tablets. Valcyclovir will be started at a dose of 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 50 500 mg orally daily if the patient is able to tolerate oral intake.  See package insert for dosing 
adjustments in patients with renal impairment.  Common side effects include headache, upset 
stomach, nausea, vomiting, diarrhea or constipation. Rare serious side effects include hemolytic 
uremic syndrome and thrombotic thrombocytopenic purpura. 
11.2.4.2 Acyclovir  
Acyclovir will be obtained by the Clinical Center Pharmacy Department from commercial  
sources.  It will be used to prevent the occurrence of herpes virus infections in patients who 
cannot take oral medications.  It is supplied as powder for injection in 500 mg/vials. Reconstitute 
in 10 mL of sterile water for injection to a concentration of 50 mg/mL. Reconstituted solutions should be used within 12 hours. IV solutions should be dilute d to a concentration of 7mg/mL or 
less and infused over 1 hour to avoid renal damage. Reversible renal insufficiency has been reported with IV but not oral acyclovir. Neurologic toxicity including delirium, tremors, coma, acute psychiatric disturbances, an d abnormal EEGs have been reported with higher doses of 
acyclovir.  Should this occur, a dosage adjustment will be made or the drug will be discontinued. 
Stomach upset, headache or nausea, rash or hives; peripheral edema; pain, elevated liver function tests; and leukopenia, diarrhea, lymphadenopathy, myalgias, visual abnormalities and elevated 
creatinine have been reported. Hair loss from prolonged use has been reported. Acyclovir will not be used concomitantly with other nucleoside analogs which interfere w ith DNA synthesis, 
e.g. ganciclovir. In renal disease, the dose is adjusted as per product labeling. 
11.2.5 Fluconazole 
Fluconazole will be obtained by the Clinical Center Pharmacy Depar tment from commercial 
sources. It will be used to prophylax against fungal infections. It is available in 200 mg tablets. It 
can cause headache, nausea, vomiting, diarrhea or abdominal pain, and liver damage which may be irreversible.  It can cause rashes and itching, which in rare cases has caused Stevens Johnson 
Syndrome. It has  several significant drug interactions. The package insert should be consulted 
prior to prescribing.  For IV administration in patients who cannot tolerate the oral preparation, 
Fluconazole comes in 2 mg/mL solution for injection, and prepared according to Clinical Center 
Pharmacy standard procedures.  It should be administered at a maximum IV rate of 200 mg/hr. 
11.2.6 Ondansetron hydrochloride 
Ondansetron hydrochloride will be obtained by the Clinical Center Pharmacy Department from commercial sources.  It will be u sed to control nausea and vomiting during the chemotherapy 
preparative regimen.  It can cause headache, dizziness, myalgias, drowsiness, malaise, and 
weakness. Less common side effects include chest pain, hypotension, pruritis, constipation and urinary rete ntion. Consult the package insert for specific dosing instructions. 
11.2.7 Furosemide 
Furosemide will be obtained by the Clinical Center Pharmacy Department from commercial sources.  It will be used to enhance urine output during the chemotherapy preparative regimen 
with cyclophosphamide. Adverse effects include dizziness, vertigo, paresthesias, weakness, orthostatic hypotension, photosensitivity, rash and pruritis.  Consult the package insert for a 
complete list of all side effects.    
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 51 12 REFERENCES  
 
1. Morgan RA, Dudley ME, Yu YYL, Zheng Z, Robbins PF, Theoret MR, et al. High 
efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of 
melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-95. 
2. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene 
therapy with human and mouse T- cell receptors mediates cancer regression and target s normal 
tissues expressing cognate antigen. Blood. 2009;114:535-46. 3. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor 
regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphoc ytes reactive with NY -ESO -1. J Clin Oncol. 2011;29:917-24. 
4. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B -lineage cells and regression of lymphoma in a patient treated with 
autologous T cells ge netically engineered to recognize CD19. Blood. 2010;116:4099-102. 
5. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine- associated toxicity in a clinical 
trial of anti -CD19 chimeric -antigen- receptor -transduced T cells. Blood. 2011;119:2709-20. 
6. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimer ic antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-51. 
7. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce s evere transient colitis. Mol Ther. 2011;19:620 -6. 
8. Suri A. Cancer testis antigens --their importance in immunotherapy and in the early 
detection of cancer. Expert Opin Biol Ther. 2006;6:379-89. 
9. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Ca ncer/testis antigens, 
gametogenesis and cancer. Nat Rev Cancer. 2005;5(615):625. 10. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for 
immunotherapy. Cancer Sci. 2009;100:2014-21. 11. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human 
lymphocytes transduced with NY- ESO -1 antigen- specific TCR genes recognize and kill diverse 
human tumor cell lines. J Immunol. 2005;174:4415-23. 
12. Wargo JA, Robbins PF, Li Y, Zhao Y, El- Gamil M, Caragacianu D, et al. Recognit ion of 
NY-ESO -1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and 
epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother. 
2009;58(383):394. 
13. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual 
amino acid substitutions in TCR CDRs can enhance antigen -specific T cell functions. J 
Immunol. 2008;180:6116-31. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 52 14. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, 
apoptosis, and neurogenetic disease . J Neurosci Res. 2002;67:705-12. 
15. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van Den Eynde B, 
et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-7. 
16. Chomez PO, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene 
family with the identification of all human members of the family. Cancer Res. 2001;61:5544-51. 
17. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma K, Bhat M, et al. MAGE- A, mMage -b, 
and MAGE -C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in 
MAGE -positive cell lines. Cancer Res. 2007;67:9954-62. 
18. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE- A 
tumor antigens target p53 transactivation function through histone deacetylase recruitment and 
confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A. 2006;103:11160-5. 
19. Liu W, Cheng S, Asa L, Ezzat S. The melanoma- associated antigen A3 mediates 
fibronectin -controlled cancer progression and metastasis. Cancer Res. 2008;68:8104-12. 
20. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary 
silencing mechanism for a set of germ line- and tumor- specific genes with a CpG -rich promoter. 
Mol Cell Biol. 1 999;19:7327-35. 
21. Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch P, Schuler G, et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res. 2005;296:314-9. 
22. Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, et al. Expression of 
cancer/testis (CT) antigens in lung cancer. Lung Cancer. 2003;42:23-33. 23. Filho PA, Lopez-Albaitero A, Xi L, Gooding W, Godfrey T, Ferris RL. Quantitative 
expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tr act cancer. Int J 
Cancer. 2009;125:1912- 20. 
24. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, et al. The clinical significance 
of MAGEA3 expression in pancreatic cancer. Int J Cancer. 2006;118:2269-75. 
25. Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, et al. Expression of cancer-
testis genes in human hepatocellular carcinomas. Cancer Immun. 2002;2:11. 
26. Han MH, Eom HS, Park WS, Yun T, Park S, Kim HJ, et al. Detection of circulating 
lymphoma cells in patients with non -Hodgkin lymphoma using MAGE- A3 gene expression in 
peripheral blood. Leuk Res. 2009. 
27. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The 
cancer -testis antigens CT7 (MAGE -C1) and MAGE -A3/6 are commonly expressed in multiple 
myeloma and correlate with plasma -cell proliferation. Blood. 2005;106:167-74. 
28. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray 
evaluation of Melanoma antigen E (MAGE) tumor- associated antigen exprewssion: potential 
indications for specific immunotherapy and prognostic relevance in squamous cell lung 
carcinoma. Ann Surg. 2002;236:785-93. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 53 29. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer- testis 
genes are coordinately expressed and are markers of poor outcome in non- small cell lung cancer. 
Clin Cancer Res. 2005;11:8055-62. 
30. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. 
Expression of cancer/testis (CT) antigens MAGE -A1, MAGE -A3, MAGE -A4, CT- 7, and NY -
ESO -1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk 
status of disease. Cancer Immun. 2003;3:9. 
31. Valkmori D, Lienard D, Waanders G. Analysis of MAGE-3- specific cytolytic T 
lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res. 1997;57:735-41. 32. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, et al. 
Identification of MAGE -3, epitopes presened by HLA-DR molecules to CD4+ T lymphocytes. J 
Exp Med. 1999;189:767-77. 
33. Manici ST, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, et al. Melanoma 
cells present a MAGE -3 epitope to CD4(+) cytotoxic T cells in association with 
histocompatibility leukocyte antigen DR11. J Exp Med. 1999;189:871-6. 
34. Schultz ES, Lethe B, Cambiaso CL, Van Snick J, C haux P, Corthals J, et al. A MAGE -
A3 peptide presented by HLA-DP4 is recognized on tumore cells by CD4+ cytolytic T 
lymphocytes. Cancer Res. 2000;60:6272-5. 
35. Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor- reactive T helper 
lymphocytes recognize  a promiscuous MAGE -A3 epitope presented by various major 
histocompatibility complex class II alleles. Cancer Res. 2001;61:4773-8. 36. Kawashima I, Hudson SJ, Tsai V. The multi-epitope approach for immunotherapy for 
cancer: identification of several CTL ep itopes from various tumor -associated antigens expressed 
on solid epithelial tumors. Hum Immunol. 1998;59:1-14. 
37. Graff -Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, et al. Generation 
of CTL recognizing an HLA-A*0201- restricted epitope shar ed by MAGE -A1, -A2, -A3, -A4, -
A6, - A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J 
Immunol. 2002;169:575-80. 38. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer 
regression and neurological toxicity following anti- MAGE -A3 TCR gene therapy. J Immunother. 
2013;36:133-51. 
39. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification 
of a Titin -derived HLA- A1-presented peptide as a cross -reactive target for engine ered MAGE 
A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03.  
40. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2- expressing tumor cells. Proc Natl Acad Sci, USA. 
1994;91:4318-22. 
41. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine leukemia by 
chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic 
Lyt-1+2- lymphocytes. J Exp Med. 1981;154(3):952-63. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 54 42. Klarnet JP, Kern DE, Okuno K, Holt C, Lilly F, Greenberg PD. FBL- reactive CD8+ 
cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus -
encoded antigens. J Exp Med. 1989;169(2):457-67. 
43. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor -specific 
Th17-polarized cells eradicate large established melanoma. Blood. 2008;112(2):362-73. 44. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell 
requirement for optimal induction of cytotoxic T lymphocytes against major  histocompatibility 
complex class II negative tumors. J Exp Med. 1998;187(5):693-702. 
45. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. 
CD8+ T cell immunity against a tumor/self -antigen is augmented by CD4+ T helper ce lls and 
hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-601. 
46. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL, Jr., et al. 
Melan -A/MART -1(51- 73) represents an immunogenic HLA -DR4 -restricted epitope recog nized 
by melanoma -reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000;97(1):400-5. 
47. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, et al. Human CD4+ T cells specifically recognize a shared melanoma- associated antigen encoded  by 
the tyrosinase gene. Proc Natl Acad Sci,USA. 1994;91:9461-5. 
48. Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, et al. 
Identification of a MHC class II -restricted human gp100 epitope using DR4- IE transgenic mice. 
J Immunol. 2000;164:3535-42. 
49. Lapointe R, Royal RE, Reeves ME, Altomore I, Robbins PF, Hwu P. Retrovirally 
transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001;167(8):4758-64. 
50. Parkhurst M, RIley JP, Robbins PF, Rosenberg SA. Induction of CD4+ Th1 lymphocytes 
that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother. 2004;27:79-91. 
51. Touloukian CE, Leitner WW, Robbins PF, Li YF, Lapointe R, Hwu P, et al. Expression 
of a "self"-antigen by human tumor cells enhance tumor angigen- specific CD4(+) T -cell 
function. Cancer Res. 2002;62:5144-7. 
52. Robbins PF, El -Gam il M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class 
II-restricted melanocyte differentiation antigens are recognized by tumor -infiltrating 
lymphocytes from a patient with melanoma. J Immunol. 2002;169:6036-47. 53. Kobayashi H, Lu J, Celis E. Identification of helper T -cell epitopes that encompass or lie 
proximal to cytotoxic T -cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 
2001;61(20):7577-84. 54. Chaux P, Lethe B, Van SJ, Corthals J, Schultz ES, Cambiaso CL, et al. A MAGE-1 
peptide recognized on HLA-DR15 by CD4(+) T cells. Eur J Immunol. 2001;31(6):1910-6. 
55. Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, et al. Identification of NY -
ESO -1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and 
recognized by CD4(+) T lymphocytes of patients with NY- ESO -1-expressing melanoma. J Exp 
Med. 2000;191(4):625-30. 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 55 56. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang R- F. CD4+ T cell recognition of 
MHC class II -restricted epitopes from NY- ESO -1 presented by a prevalent HLA DP4 allele: 
Association with NY -ESO -1 antibody production. Proc Natl Acad Sci. 2001;98:3963-9. 
57. Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, et al. 
Identification of an SSX -2 epitope presented by dendritic cells t o circulating autologous CD4+ T 
cells. J Immunol. 2004;172(11):7206-11. 
58. Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, et al. CD4+ T 
cell responses to SSX -4 in melanoma patients. J Immunol. 2005;174(8):5092-9. 
59. Hunder NN, Wall en H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of 
metastatic melanoma with autologous CD4+ T cells against NY -ESO -1. N Engl J Med. 
2008;358:2698-703. 
60. Gaugler B, Van Den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et 
al. Human gene MAGE -3 codes for an antigen recognized on a melanoma by autologous 
cytolytic T lymphocytes. J Exp Med. 1994;179:921-30. 
61. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, et al. 
Tumor -specific shared antigenic p eptides recognized by human T cells. Immunol Rev. 
2002;188:51-64. 
62. Francois V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, et al. The 
CD4(+) T -cell response of melanoma patients to a MAGE -A3 peptide vaccine involves potential 
regulatory T cells. Cancer Res. 2009;69(10):4335-45. 
63. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of 
murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Canc er Res. 2006;66:8878-86. 
 
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 56 13 FIGURES, TABLES & APPENDICES  
Figure 1  
  

Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 57 Figure 1. Comparison of reactivity of T cells transduced with three TCR that recognize the 
MAGE -A3:245-258 HLA class II restricted epitope (a) PBMC from three  melanoma patients 
were stimulated with OKT3 and transduced on day 2, and evaluated six days later for expression 
of the transduced TCRs using the appropriate anti- TCR Vβ antibodies. Un-transduced cells 
incubated with the anti-V β22 antibody demonstrated re latively low levels of endogenous cell 
surface expression of this TCR. (b) CD4+ T cells from the three patient PBMC that had been 
transduced with the 6F9, R12C9 and 12C7 TCRs were isolated by using a CD4 T lymphocyte 
enrichment kit (Life Technologies, Grand Island, NY). The isolated T cells (105) were cultured 
with either HLA -DP*0401+ 293- CITTA cells (105) that were transiently transfected with plasmid 
constructed encoding individual MAGE family members, 293- CIITA cells that were pulsed with 
the 10 µ g/mL of the MAGE -A3:245-258 peptide. In addition, transduced CD4+ T cells were 
cultured with 105 1359 mel -CIITA cells, which express MAGE -A3 as well as HLA -DP*0401, or 
624 mel -CIITA cells, which express MAGE -A3 but do not express HLA -DP*0401 or 0402. 
Following an overnight co-culture, the levels of soluble IFN- γ were evaluated by ELISA. (c ) 
CD4+ T cells transduced with the three MAGE -A3 TCRs (105) were incubated with 293- CIITA 
cells (105) that were pulsed with the indicated concentrations of the MAGE -A3:245-258 peptide 
for two hours at 370C. Following the incubation, the target cells were w ashed twice and co -
cultured overnight with CD4+ T cells from PBMC 1, and the release of soluble IFN- γ measured 
by ELISA.  
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 58 Figure 2 
  

Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 59 Figure 2. Comparison of responses of CD4+ and CD8+ T cells transduced with the 6F9 TCR or 
the 6F9 TCR containing murine constant region sequences (6F9mc). (a) Evaluation of responses 
of CD4+ and CD8+ T cells isolated from two patient PBMC against MAGE -A3+ and MAGE -A3- 
tumor cells that express HLA -DP*0401, 0402, or lack expression of either HLA- DP allele.  
Targets include 8 melanoma cell lines (2630 mel -CIITA, 397 mel-CIITA,2984-CIITA, 526 mel-
CIITA, 1359 mel- CIITA, SK37 mel -CIITA, 3071 mel-CIITA, and 624 mel- CIITA), one non -
small cell lung carcinoma (H1299 NSCLC -CIITA), and one renal cancer cell line (1764 RCC-
CIITA). (b) Evaluation of responses of CD4+ T cells that were transduced with either the 6F9 or 
the 6F9mc TCR against tumor targets. (c)  Evaluation of responses of CD8+ T cells that were 
transduced with either the 6F9 or the 6F9mc TCR against tumor targets. Co- cultures were carried 
out as described in Figure 1. 
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 60 
Figure 3 
 
   
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 61 Figure 3. Flow cytometric analysis of T cells for patient infusion.  Peripheral blood lymphocytes 
were CD8+ T cells depleted on day 0 and transduced with MAGE -A3 DP4 TCR  on day 2 and 3. 
Cells were subjected to flow cytometric analysis on day 9 (A). Cells on day 13 after rapid 
expansion were also subjected to flow cytometric analysis (B). Unseparated, un -transduced 
lymphocytes functioned as the negative control. R epresentative data from one of the three different 
donors  are shown.  
 
    
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 62 
Figure 4 
 
 
  A  
 
      
  B 
        
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 63  
Figure 4. Recognition of MAGE -A3+, DP0401+ tumor cell line and  MAGE -A3 DP4 peptide -
pulsed cells. On day 10 after CD8+ T cell depletion (A) or day 13 after rapid expansion (B) , 
MAGE -A3 DP4 TCR -transduced CD4+ T cells were co -cultured for 16 hr with tumor target cell 
lines (2630 CIITA: MAGE -A3+, DP0401+; 624 CIITA: MAG E-A3+, DP0401-; 1764 CIITA: 
MAGE -A3-, DP0401+) or MAGE -A3 DP4 peptide- pulsed 293 CIITA cells. The secretion of IFN -
gamma was determined by ELISA. R epresentative data from one of the three different donors  are 
shown. 
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 64  
Table 1 
Table 1. Evaluation of response to peptides related to MAGE -A3:243 -258  
a
bAmino acids 243 -258
MAGE -A3 KKLLTQHFVQENYLEY
MAGE -A6 KKLLTQ YFVQENYLEY
MAGE -A1 KKLLTQ DLVQE KYLEY
MAGE -A12 KKLLTQ DLVQENYLEY
*CD4+T cells isolated from two patient PBMC by negative selection were transduced with  either 
the  6F9 TCR, the 6F9mc TCR, or were un -transduced  and assayed 10 days following OKT3 
stimulation for their response to 293 -CIITA cells that were pulsed with 10 µg/ml of the indicated 
peptides, as described in Figure 1.PBMC -1* transduced with: PBMC -2  transduced with:
6F9 6F9mc None 6F9 6F9mc None Predicted
Gene (position) Amino Acid Sequence IFN-γ(pg/ml) affinity( nM)
MAGE -A3:243 -258KKLLTQHFVQENYLEY 10,220 15,210 33 10,350 17,520 45 3
MAGE -A3:243 -256KKLLTQHFVQENYL  1,018 1,815 72 1,670 2,490 78 323
MAGE -A3:243 -255KKLLTQHFVQENY   76 137 29 111 117 71 378
MAGE -A3:243 -254KKLLTQHFVQEN 28 0 67 30 39 78 466
MAGE -A3:243 -253KKLLTQHFVQE 0 40 38 30 45 90 2444
MAGE -A3:245 -258LLTQHFVQENYLEY 9,290 14,970 84 8,920 17,820 74 3
MAGE -A3:246 -258LTQHFVQENYLEY 7,140 12,700 56 9,200 16,170 76 3
MAGE -A3:247 -258TQHFVQENYLEY 6,710 10,600 30 6,810 13,280 41 3
MAGE -A3:248 -258 QHFVQENYLEY 6,220 9,000 52 7,400 8,700 56 4
MAGE -A3:249 -258 HFVQENYLEY 669 1,643 57 922 2,034 66 5
MAGE -A6:248 -258 QYFVQENYLEY 6,440 11,800 54 13,200 8,370 127 3
MAGE -A2/A12:248 -258 QDLVQENYLEY 33 66 49 37 56 65 59
MAGE -A4/A9:249 -259 QDWVQENYLEY 0 23 32 22 26 62 92
MAGE -A8:251 -261 QEWVQENYLEY 43 58 79 39 41 55 87
MAGE -A1/B4:241 -251 QDLVQEKYLEY 129 126 55 108 84 53 16
MAGE -B2:250 -260 KDLVQEKYLEY 0 0 43 7 20 38 16
MAGE -B10:250 -260 KDLVKENYLEY 22 18 69 28 34 66 105
MAGE -B16:252 -262 KDFVKEKYLEY 0 27 16 11 28 42 3
MAGE -C1:113 -123 KVWVQEHYLEY 9 0 30 25 27 30 35
MAGE -D4:300 -315RKLITDDFVKQKYLEY 193 234 81 194 268 80 6
MAGE -D2:413 -428KKLITDEFVKQKYLDY 82 43 56 226 223 71 8
MAGE -L2:582 -597KKLITEVFVRQKYLEY 45 56 58 78 107 114 6
MAGE -G1:220 -235KKLITEDFVRQRYLEY 0 29 68 25 33 62 3
Necdin:237 -247 EEFVQMNYLKY 0 22 59 21 32 83 13
No peptide 0 5 58 15 25 59
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 65 Appendix 1 
Modification of Dose Calcul ations* in patients  whose BMI is greater than 35  
Unless otherwise specified in this protocol , actual body weight is used for dose 
calculations of treatment agents. In patients who are determined to be obese (BMI > 
35), the practical weight  (see 3 below) will be used. 
 
 
1. BMI Determination: 
 
BMI = weight (kg) / [height (m)]2 
  
2. Calculation of ideal body weight 
 
Male = 50 kg + 2.3 (number of inches over 60 inches) 
Example:  ideal body weight of 5’10’’ male 
50 + 2.3 (10) = 73 kg  
Female = 45.5 kg + 2.3 (number of inches over 60 inches) 
Example:  ideal body weight of 5’3’’ female 
45.5 + 2.3 (3) = 57 kg  
3. Calculation of “practical weight”  
 
Calculate the average of the actual and the ideal body weights. This is the 
practical weight to be used in calculating the doses of chemotherapy and 
associated agents designated in the protocol. 
 
  
 
 
 
 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 66  
Appendix 2  
Adverse Events Occurring In ≥10% Of Patients Treated With Aldesleukin (N=525)1 
Body System   % Patients   Body System    % Patients  
Body as a Whole      Metabolic and Nutritional Disorders  
Chills     52   Bilirubinemia    40 
Fever     29   Creatinine increase   33 
Malaise    27   Peripheral edema   28 
Asthenia    23   SGOT increase   23 
Infection    13   Weight gain    16 
Pain     12   Edema    15 
Abdominal pain   11   Acidosis    12 
Abdomen enlarged   10   Hypomagnesemia   12 
Cardiovascular     Hypocalcemia   11 
Hypotension    71   Alkaline phosphatase incr  10 
Tachycardia    23  Nervous  
Vasodilation    13   Confusion    34 
Supraventricular tachycardia  12   Somnolence    22 
Cardiovascular disordera  11   Anxiety    12 
Arrhythmia    10   Dizziness    11 
Digestive      Respiratory  
Diarrhea    67   Dyspnea    43 
Vomiting    50   Lung disorderb   24 
Nausea    35   Respiratory disorderc   11 
Stomatitis    22   Cough increase   11 
Anorexia    20   Rhinitis    10 
Nausea and vomiting   19   Skin and Appendages  
Hemic and Lympha tic    Rash     42 
Thrombocytopenia   37   Pruritus    24 
Anemia    29   Exfoliative dermatitis   18 
Leukopenia    16   Urogenital  
Oliguria    63 
a Cardiovascular disorder: fluctuations in blood pressure, asymptomatic ECG changes, CHF.  
b Lung disorder: physical findings associated with pulmonary congestion, rales, rhonchi.  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 67 c Respiratory disorder: ARDS, CXR infiltrates, unspecified pulmonary changes. 
1Source: Proleukin® Prescribing Information – June 2007  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 68 Appendix 3 
Expected IL -2 Toxicities and their Management  
Expected toxicity  Expected 
grade  Supportive Measures  Stop Cycle*  
 Stop 
Treatment **  
Chills  3 IV Meperidine 25 -50 
mg, IV q1h, prn,  No No 
Fever  3 Acetaminophen 650 
mg, po, q4h; 
Indomethicin 50-75 
mg, po, q8h  No No 
Pruritis  3 Hydroxyzine HCL 
10-20 mg po q6h, prn; Diphenhydramine HCL25 -50 mg, po, 
q4h, prn  No No 
Nausea/ Vomiting/ 
Anorexia  3 Ondansetron 10 mg, 
IV, q8h, prn; Granisetron 0.01 mg/kg IV daily prn; Droperidol 1 mg, IV q4-6h, prn; Prochlorperazine 25 mg pr, prn or 10 mg 
IV q6h prn  No No 
Diarrhea  3 Loperamide 2mg, po, 
q3h, prn; Diphenoxylate HCl 2.5 mg and atropine sulfate 25 mcg, po, q3h, prn; codeine sulfate 30-60 mg, po, 
q4h, prn  If uncontrolled after 24 
hours despite all supportive measures  No 
Malaise  3 or 4  Bedrest  If other toxicities occur 
simultaneously  No 
Hyperbilirubinemia  3 or 4  Observation  If other toxicities occur 
simultaneously  No 
Anemia  3 or 4  Transfusion with 
PRBCs  If uncontrolled despite 
all supportive measures  No 
Thrombocytopenia  3 or 4  Transfusion with 
platelets  If uncontrolled despite 
all supportive measures  No 
Edema/Weight gain  3 Diuretics prn  No No 
Hypotension  3 Fluid resuscitation  
Vasopressor support  If uncontrolled despite 
all supportive measures  No 
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 69 Dyspnea  3 or 4  Oxygen or 
ventilatory support  If requires ventilatory 
support  No 
Oliguria  3 or 4  Fluid boluses or 
dopamine at renal 
doses  If uncontrolled despite 
all supportive measures  No 
Increased creatinine  3 or 4  Observation  Yes (grade 4)  No 
Renal failure  3 or 4  Dialysis  Yes Yes 
Pleural effusion  3 Thoracentesis  If uncontrolled despite 
all supportive measures  No 
Bowel perforation  3 Surgical intervention  Yes Yes 
Confusion  3 Observation  Yes No 
Somnolence  3 or 4  Intubation for airway 
protection  Yes Yes 
Arrhythmia  3 Correction of fluid 
and electrolyte 
imbalances; chemical conversion or electrical conversion 
therapy  If uncontrolled despite 
all supportive measures  No 
Elevated Troponin 
levels  3 or 4  Observation  Yes If changes in 
LV function have not improved to baseline by 
next dose  
Myocardial 
Infarction  4 Supportive care  Yes Yes 
Elevated 
transaminases  3 or 4  Observation  For grade 4  without 
liver metastases  If changes 
have not improved to baseline by 
next dose  
Hyperbilirubinemia  3 or 4  Observation  For grade 4 without 
liver metastases  If changes 
have not improved to baseline by 
next dose  
Electrolyte 
imbalances  3 or 4  Electrolyte 
replacement  If uncontrolled despite 
all supportive measures  No 
Neutropenia  4 Observation  No No 
*Unless the toxicity is not reversed within 12 hours 
** Unless the toxicity is not reversed to grade 2 or less by next treatment.  
   
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 70 Appendix 4   
Interleukin -2 toxicities observed in patients treated at the NIH Clinical Center   
    
 
  
Abbreviated Title: Anti- MAGE -A3-DP4 TCR PBL  
Version Date: June 22, 2018  
 71 Appendix 5   
Certificate of Analysis  
Infused T cells transduced with MAGE -A3 DP0401/0402 TCR genes.  
Date of preparation of final product:  
Patient: 
Tests performed on final product:  
 
Test 
 Method  Limits  Result  Tests 
Performed 
by Initials/  
Date 
Cell viability1 trypan blue exclusion  >70%     
Total viable cell 
number1 visual microscopic count  >1 x107    
Tumor reactivity2 γ-IFN release vs. peptide 
pulsed 293- CIITA  cells >200 pg/m L, and > 2 
times background     
TCR expression2 FACS analysis of the 
transduced cells  PBL, >10%     
Microbiological 
studies  gram stain1,3,  no micro -organisms 
seen    
 aerobic culture3,4 no growth     
 fungal culture3,4 no growth     
 anaerobic culture3,4 no growth     
 mycoplasma test5 negative     
Endotoxin  limulus assay1 ≤ 5 E.U./kg     
RCR S+L- Assay4 
RCR -PCR6  
negative     
1 Performed on sample of the final product immediately prior to infusion.  Results are available at the time of infusion.  
2 Performed 2 -10 post transduction. Results are available at the time of infusion.  
3 Performed 2 -4 days prior to infusion.  Results are available at the time of infusion but may not be definitive.  
4 Sample collected from the final product prior to infusion.  Results will not be available before cells are infused into the patient.  
5 Performed 2 -10 days prior to infusion.  Results are available at the time of infusion. 
6 Performed on sample approximately 1-4 days prior to infusion.  Results are available at the t ime of infusion.  
 
Prepared by:  _______________________________________ Date:  ____________________ 
  
QC sign -off: _______________________________________ Date:  ____________________ 
Qualified Clinical or Laboratory Supervisor  
 
 